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Our overall goal of this investigation was to broaden our understanding of MDD-SI.  
Specifically, we sought to document the associated features of MDD-SI, understand the 
phenomenology of MDD-SI, develop a clinical phenotype of MDD-SI, and discern whether the 
MDD-SI phenotype is associated with an unfavorable or differential initial response to treatment.  
We conceptualized this work as a preliminary investigation of the specific treatment needs of 
individuals with MDD-SI and potential identification of one subset of individuals who fail to 
experience an initial response to first-line monotherapies for major depression.   
To this end, we completed a secondary analysis of data from a two-site, cross-national 
clinical trial in which individuals presenting in an episode of major depression were randomly 
allocated to an initial treatment protocol consisting of SSRI antidepressant pharmacotherapy 
(SSRI) or interpersonal psychotherapy (IPT).  
In comparisons between individuals with MDD-SI and individuals without current, 
baseline suicidal ideation (MDD), we found that (1) few pre-treatment socio-demographic or 
baseline clinical characteristics significantly distinguished MDD-SI and MDD, (2) lifetime 
experiences of suicidal ideation and suicidal behavior were significantly different between 
MDD-SI and MDD, and (3) lifetime history and past month experiences of some mood and
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panic-agoraphobic spectrum symptoms were significantly different between MDD-SI and MDD.  
In addition, we demonstrated that MDD-SI is negatively associated with initial treatment 
response, such that individuals with MDD-SI were significantly more depressed after six weeks 
of treatment than were individuals with MDD.  Nonetheless, after six weeks of treatment, 
interviewer-rated suicidal ideation resolved for over 90% of individuals with MDD-SI and self-
reported suicidal ideation resolved for all but about 11%.  
Our findings provide preliminary support for the usefulness of assessing both syndromal 
and subsyndromal manifestations of major depression, establishing a lifetime assessment of 
suicidality as routine clinical practice, and conceptualizing MDD-SI as a subtype and clinical 
phenotype of major depression.  Further research, including replication of our findings, is 
needed. 
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1.0  INTRODUCTION 
Despite an arsenal of empirically-supported psychotherapies and pharmacotherapies for the 
treatment of unipolar major depression, the extant literature offers the practicing clinician little 
guidance for selecting an initial psychotherapy or pharmacotherapy treatment strategy (Frank et 
al., 2010; Gelenberg, 2010).  Consequently, the proportion of individuals who access treatment 
and experience an initial response to first-line treatment is disappointingly small, rarely 
exceeding 50% (Cassano et al., 2009; Kessler et al., 2003a; Trivedi, Fava, Marangell, Osser, & 
Shelton, 2006).  Indeed, according to the World Health Organization (WHO), less than 25% of 
individuals with major depression receive adequate treatment (WHO, 2005).  Moreover, for a 
minority of individuals suffering from major depression, psychosocial and pharmacological 
treatments fail not only to reduce depressive symptomatology but also to halt the “suicidal 
process,” or an individual’s progression from mild to more severe forms of suicidality 
(Baldessarini et al., 2007; Joiner, 2005; Neeleman, de Graaf, & Vollebergh, 2004).   
One way to increase response rates and the overall effectiveness of first-line treatment for 
major depression might be to identify clinical phenotypes within the disorder, and then determine 
if the defining symptoms and features moderate treatment response.  Isolating clinical 
phenotypes to determine treatment needs and guide treatment selection is a potentially fruitful 
method, and may be more consistent with data from both treatment trials and biological 
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investigations (Cassano et al., 2009; Perlis et al., 2009).  For example, there is substantial 
evidence that not all treatments work equally well for all individuals and that individual 
differences account for some of the variance in treatment response (Frank et al., 2000; 
Gelenberg, 2010; Stiles, Shapiro, Elliott, 1986).  Some of these individual differences may be 
associated with a distinct clinical phenotype of major depression and, accordingly, specific 
treatment needs. 
One potential clinical phenotype that has received relatively little attention is major 
depression with current suicidal ideation (MDD-SI) (Joiner, 2005; Oquendo, Baca-Garcia, Mann, 
& Giner, 2007).  Suicidal ideation refers to thoughts of engaging in suicide-related behavior, 
with varying degrees of severity and elaboration (Brenner et al., 2010).  It fluctuates within and 
among individuals in terms of presence, duration, frequency, persistence, depth, and intensity 
(Joiner, 2005; Joiner et al., 2003; Valtonen et al., 2009).  Suicidal ideation falls on a broad 
continuum of suicidality.  This continuum comprises a constellation of cognitions and suicidal 
behaviors, including fleeting and passive death wishes or escape fantasies, verbalization of 
suicidal ideation, risky and reckless behaviors, attempt planning and preparatory behaviors, 
repeated suicide attempts, and completed suicide (Brenner et al., 2010; Casey et al., 2008; Witte, 
Fitzpatrick, Joiner, & Schmidt, 2005).  The suicidal trajectory may be either peripatetic with 
sudden jumps in intensity or follow a continuous progression of increasing severity (De Leo, 
Cerin, Spathonis, & Burgis, 2005; Joiner, 2005; Kessler, Borges, & Walters, 1999; Kessler, 
Ormel, Demler, & Stang, 2005; Nock et al., 2008b).  
The phenomenology and clinical implications of suicidal ideation are complex.  On one 
hand, among a minority of individuals, suicidal ideation is a marker for future risk (Gunnell, 
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Harbord, Singleton, Jenkins, & Lewis, 2004; Joiner, 2005; Valtonen et al., 2009).  It is a 
precursor to more serious suicidal behavior, including death (Kessler et al., 1999, 2005; Konick 
& Gutierrez, 2005).  On the other hand, suicidal ideation is a prevalent psychological, or 
cognitive, symptom of depression (Cox, Enns, & Clara, 2004; Michal et al., 2010).  It is an 
extreme form of suffering and negative self-referent thinking (Williams, Crane, Barnofer, Van 
der Does, & Segal, 2006).  Then again, suicidal ideation also is an indicator of current distress, 
disease presence, and illness severity (Minnix, Romero, Joiner, & Weinberg, 2007; Scocco, 
Girolamo, Vilagut, & Alonso, 2008).  It is this very intricacy, this diversity in meanings, which 
highlights the potential clinical and empirical utility of defining the MDD-SI clinical phenotype.  
In fact, some researchers have suggested that suicidality should be a separate diagnostic category 
in the next edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM) 
(Leboyer, Slama, Siever, & Bellivier, 2005; Oquendo et al., 2008).  In addition, there is some 
evidence that suicidal ideation is highly consistent across depressive episodes; only the severity 
seems to fluctuate (Antypa, Van der Does, & Pennix, 2010; Borges, Angst, Nock, Ruscio, & 
Kessler, 2008).  That is, once suicidal ideation emerges, it often resurfaces during future episodes 
(Williams et al., 2006; Witte et al., 2005).  Thus, the MDD-SI clinical phenotype might be able 
to distinguish individuals not only acutely but also longitudinally.  
Yet, our understanding of suicidal ideation, especially in the absence of suicidal 
behaviors, is quite limited.  The present literature tells us little about exactly who experiences 
MDD-SI, what distinguishes these patients from others, or whether this phenotype is associated 
with an unfavorable response to treatment.  It tells us nothing about whether psychotherapy or 
pharmacotherapy is a preferable initial treatment strategy for MDD-SI (Baldessarini et al., 2007; 
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Heisel, Duberstein, Talbot, King, & Tu, 2009; Pompili et al., 2010; Szanto, Mulsant, Houck, 
Dew, & Reynolds, 2003). 
A first step to increasing our understanding of these issues is developing a rich clinical 
phenotype of MDD-SI.  To this end, the Spectrum Assessment Method (Cassano et al., 1997, 
2004) seems particularly well suited.  This method produces phenotypes characterized by an 
array of prodromal, subsyndromal, syndromal, and temperamental manifestations of the target 
disorder.  Consequently, it provides a range of symptoms for specific treatments to address 
(Cassano et al., 1997; Frank et al., 2000).  Furthermore, the Spectrum Assessment Method holds 
promise for the identification of symptoms or associated features that account for potential 
variance in initial treatment response.  Indeed, if it becomes evident that individuals with MDD-
SI are distinct from individuals without suicidal ideation and/or that individuals with MDD-SI 
respond poorly to first-line treatments, we can use the phenotype generated from the Spectrum 
Assessment Method to great benefit.  Specifically, with this phenotype we can adapt treatments, 
or develop new treatments, to target both the suicidal ideation and the associated prodromal, 
subsyndromal, and syndromal symptomatology. 
 In sum, one way to increase response rates and the overall effectiveness of first-line 
treatment for major depression might be to identify clinical phenotypes that account for some of 
the variance in initial treatment response.  Considering the generally low initial treatment 
response rate, coupled with the sometimes rapid or persistent nature of suicidal ideation, there 
are clear benefits of delineating the clinical phenotype and initial treatment needs of MDD-SI.  
Conceivably, if the proportion of individuals with MDD-SI who respond to an initial treatment is 
increased, then both the depression- and suicide-related disease burden will decrease (Dew et al., 
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2001).  There would be an optimization of treatment that, in turn, would reduce individuals’ time 
to recovery, extend well-intervals between episodes, obviate the need for unnecessary exposure 
to somatic treatments, and decrease healthcare cost (Trivedi et al., 2006). 
Against this background, we sought to (1) document the associated features of MDD-SI, 
(2) develop a clinical phenotype of MDD-SI by adopting the Spectrum Assessment Method, and 
(3) discern whether the MDD-SI phenotype is associated with an unfavorable or differential 
initial response to empirically-supported SSRI antidepressant pharmacotherapy (SSRI) or 
interpersonal psychotherapy (IPT) for major depression.  For this investigation, we defined 
MDD-SI as a non-psychotic unipolar major depressive episode with current suicidal ideation. 
1.1 SPECIFIC AIMS 
To this end, we completed a secondary analysis of data from a two-site, cross-national clinical 
trial in which individuals presenting for treatment of a non-psychotic unipolar major depressive 
episode were randomly allocated to a treatment protocol involving SSRI, IPT, and, in the 
absence of a response or sustained remission, their combination.  We examined: 
 The pre-treatment socio-demographic and baseline clinical characteristics associated with 
baseline suicidal ideation, to document the associated features of MDD-SI; 
 The lifetime and past month mood and panic-agoraphobic spectrum conditions associated 
with baseline suicidal ideation, to understand the phenomenology of MDD-SI and 
develop a clinical phenotype of MDD-SI; and  
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 The initial response to six weeks of monotherapy with either SSRI or IPT of individuals 
with baseline suicidal ideation, to discern whether MDD-SI is associated with an 
unfavorable or differential initial response to treatment. 
 
In the next section, we concentrate on providing an overview of past research that is 
particularly relevant to these aims.  This includes the (1) methods for assessing suicidal ideation, 
(2) prevalence of suicidal ideation, (3) major correlates of suicidal ideation, (4) relationship 
between suicidal ideation and treatment response, (5) association between subsyndromal mood 
and anxiety symptoms and treatment response, and (6) Spectrum Assessment Method.  Then, we 
conclude with a presentation our hypotheses. 
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2.0  BACKGROUND AND SIGNIFICANCE 
2.1 ASSESSING SUICIDAL IDEATION 
The study of suicidal ideation is challenging (Bongiovi-Garcia et al., 2009; De Leo et al., 2005; 
Valtonen et al., 2009).  One reason is that suicidal ideation is a broad term without precise 
endpoints (Mission et al., 2010), and there is limited consensus about what exactly constitutes 
suicidal ideation (Brenner et al., 2010; Fawcett, Baldessarini, Coryell, Silverman, & Stein, 2009). 
Recently, to promote a common lexicon among mental health researchers and clinicians, Brenner 
and colleagues (2010), in collaboration with the Centers for Disease Control and Prevention 
(CDC), developed the Classification System of Self-Directed Violence (CSSV).  Accordingly, 
suicidal ideation is defined as “self-reported thoughts of engaging in suicide-related behavior.”  
Importantly, it does not include self-reported thoughts regarding an individual’s desire to engage 
in self-inflicted, potentially injurious behavior without suicidal intent.  Furthermore, anything 
beyond verbalizations or thoughts, such as acts or preparations (e.g., giving belongings away or 
hoarding medication for a potential over-dose), is classified as suicidal behavior.  Notably, to 
date, most research is inconsistent with the CSSV.  Mainly, many investigators group together 
individuals with suicidal ideation and individuals with mild suicidal behaviors (Brown, 2000; 
Mission et al., 2010).  
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Another reason the study of suicidal ideation is difficult is that suicidal ideation is hard to 
evaluate, and there is little consensus regarding the “best” method for assessing it (Nock et al., 
2010; Valtonen et al., 2009).  Namely, factors at both the individual- and methodological-level 
influence the validity and reliability of suicidality assessments, problems that the personal and 
variable nature of suicidal ideation exponentiate (Brown, 2000).   
Individual-level factors include the subjectivity of suicidal ideation and the fear and 
stigma associated with suicidality.  Depending on the elaboration, intensity, and effect of these 
thoughts, an individual may not report current or recall past suicidal ideation (Joiner et al., 2009; 
Szanto et al., 2001; Vannoy et al., 2007).  He or she may not see it as relevant, noteworthy, or 
memorable (Goldney et al., 2009; Nock et al., 2010; Scocco et al., 2008; Valtonen et al., 2009).  
Conversely, he or she may see his or her experience with suicidal thoughts as important and 
significant but conceal such experiences because of concerns about hospitalization, fear of 
stigma and judgment, or feelings of shame, guilt, and embarrassment (Apter, Horesh, Gothelf, 
Graffi, & Lepkifker, 2001; Deane & Todd, 1996; Levinson, 2008; Scocco et al., 2008). 
Methodological-level problems include the documented discrepancies between self-
report and interviewer-rating scales, between semi-structured (e.g., SCID) and unstructured (e.g., 
clinical interview) assessments, and the failure of many assessments to differentiate among 
dimensions of suicidality (Nock et al., 2008b, 2010).  Consequently, there is variability in the 
sensitivity (true positives) and specificity (true negatives).  For example, Valtonen and 
colleagues (2009) explored how different assessment methods influenced which individuals in 
their sample were classified as current “suicidal ideators.”  Their assessments included asking 
individuals whether they had ever seriously considered suicide during the current affective 
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episode (an unstructured, interviewer-rating), requesting individuals to complete the structured 
self-report Beck Depression Inventory (BDI) (Beck, Ward, Mendelson, Mock, & Erbaugh, 
1961), and administering both the structured, interviewer-rating Scale for Suicidal Ideation (SSI) 
(Beck, Kovacs, & Weissman, 1979) and Hamilton Rating Scale for Depression (HRSD) 
(Hamilton, 1960).  Valtonen and colleagues report that, among their sample of 191 individuals 
with bipolar disorder, whereas 74% were classified as suicidal ideators by at least one method, 
only 29% were classified as suicidal ideators by all methods.  Moreover, the SSI was only 
moderately correlated with the BDI (r = .58) and HRSD (r = .67) suicide items, and agreement of 
who was an ideator ranged from low to moderate (kappa coefficient 0.15 to 0.70).  Likewise, 
Bongiovi-Garcia and colleagues (2009) investigated the agreement between structured (SSI) and 
unstructured (general clinical interview) interviewer-rated suicidality among 201 inpatients with 
unipolar or bipolar depression.  They found only fair agreement for the presence of suicidal 
ideation; while structured assessments captured all inpatients identified as having suicidal 
ideation by unstructured assessments, unstructured assessments failed to identify 29.7% of 
inpatients identified by structured assessments.  In another study, Bridge, Barbe, Birmaher, 
Kolko, and Brent (2005) demonstrated that, among 88 medication-free adolescent outpatients 
with major depression, self-reported suicidality was of significantly greater predictive value than 
was interviewer-rated suicidality.  Similarly, in a sample of 328 young adults, Joiner, Rudd, and 
Rajab (1999) found discrepancies between self-reported and interviewer-rated suicidality, such 
that half of the sample who self-rated as low in suicidality were interviewer-rated as high in 
suicidality.  Notably, their analyses of follow-up data of incidence of post-interview suicidal 
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behaviors suggested that, overall, interviewers over-estimated suicidality, particularly when the 
individual reported a previous suicide attempt or exhibited histrionic personality features.   
Taken together, these findings suggest that each method for assessing suicidal ideation is 
somewhat flawed, and therefore, the "best" method might be an all-inclusive, comprehensive and 
structured approach (Brown, 2000; Joiner, Walker, Pettit, Perez, & Cukrowicz, 2005b; Valtonen 
et al., 2009).  Yet, the current literature suggests that most investigators rely on a single method.  
For example, in a meta-analysis of treatment-emergent suicidality, Beasley et al. (2007) found 
that 16 of 18 clinical trials of fluoxetine for major depression assessed suicidality with one item 
on a depressive symptom rating scale, Question 3 on the HRSD.  This question directly assesses 
suicidality using the anchors: 0 = "absent," 1 = "feels life is not worth living," 2 = "wishes he/she 
were dead or any thoughts of possible death to self," 3 = "suicide ideas or gestures," and 4 = 
"attempts at suicide.”  Notably, researchers have demonstrated that this single interviewer-rating 
of suicidality has high inter-rater reliability (r = .92; Reynolds, 1991), adequate test-retest 
reliability (r = .64; Williams, 1988), and strong concurrent and predictive validity (Brown, 2000).  
Nonetheless, the widespread use of this single question more likely reflects the extensive use of 
the HRSD as a "gold standard" in clinical trials rather than its validity as an assessment of 
suicidality.   
The frequent use of the HRSD highlights another assessment issue, and a potential 
limitation of the retrospective use of depressive symptom scales: severity but little else is 
detailed.  The HRSD question provides a score that essentially indicates only the current absence 
or presence of ideation and action.  Ideation is less severe than is action, and higher scores reflect 
increased suicide risk – unmistakably, a distinction of important clinical concern.  Yet, Joiner 
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and his group (Joiner et al., 2003, 2009; Witte et al., 2005) present data that suggests certain 
presumed and potential dimensions of suicidal ideation are more predictive of risk than are other 
dimensions of suicidal ideation; the HRSD item – and similar symptom measures – fails to 
differentiate among these elements (Brown, 2000).   
Joiner and colleagues submit that the structure of suicidal ideation is multidimensional 
(Beck & Lester, 1976; Joiner et al., 2009; Witte et al., 2005; Steer, Rissmiller, Ranieri, & Beck, 
1993).  Specifically, they argue that suicidal ideation is adequately explained by two factors, 
namely “resolved plans and preparations” and “suicidal desire and ideation.”  The resolved plans 
and preparations factor comprises a sense of courage and competence to make an attempt, 
availability of means and opportunity to make an attempt, specificity of plan, and preparations 
for attempt.  The suicidal desire and ideation factor involves reasons for living (negatively 
loaded), wish to die, wish not to live, passive attempt, desire for attempt, lack of deterrents to 
attempt, and talk of death or suicide.  Joiner and his team theorize that the resolved plans and 
preparations factor is facilitated by previous suicidality.  Specifically, past experiences with 
suicidal ideation allow the individual to habituate to the fear, pain, and taboo associated with 
self-harm.  Accordingly, previous experiences with suicidality provide the individual with 
practice, and in turn, increase an individual’s confidence and competence – he or she acquires 
the ability to engage in suicidal behaviors.  Similarly, these previous experiences wear on the 
individual such that he or she experiences increased resolve and commitment to suicidal 
behaviors.  Thus, for predictive purposes, previous and “worst-point” suicidal ideation might be 
more important than is current suicidal ideation (Beck, Brown, Steer, Dahlsgaard, & Grisham, 
1999; Joiner et al., 2003; Witte et al., 2005).  For the purpose of defining a clinical phenotype 
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and investigating initial treatment response, the value of current suicidal ideation compared to 
previous and worst-point is unclear. 
To summarize, potential limitations of research on suicidal ideation include the lack of a 
widely-used nomenclature of suicidality, the heterogeneity of suicidal ideation, the over-reliance 
on a single interviewer-rating of suicidality and, to a lesser extent, a single self-report rating of 
suicidality, and the inability of many assessments to differentiate among potential dimensions of 
suicidality.  Individual and methodological heterogeneity, coupled with the ensuing variance in 
sensitivity and specificity, influences the epidemiological estimates, correlates, and predictive 
value of suicidal ideation.   
2.2 THE PREVALENCE OF SUICIDAL IDEATION 
Thinking about suicide is much more common than is dying by suicide (Jamison, 1999).  In 
general, as the severity of suicidality increases, the prevalence decreases (Kessler et al., 1999, 
2005).  For example, estimates of the lifetime prevalence of suicidal ideation range between 
4.8% and 18.5% (Bernal et al., 2007; Paykel, Myers, Lindenthal, & Tanner 1974), whereas 
estimates of the lifetime prevalence of suicide attempts range between 1.1% and 4.3% (Kessler et 
al., 1999). Prevalence estimates, however, are influenced by methodological and assessment 
heterogeneity, including sampling techniques (De Leo et al., 2005).  Prevalence estimates of 
lifetime suicidal ideation vary considerably across age-cohorts, general and clinical-populations, 
and countries and geographical areas (Bernal et al., 2007; Casey et al., 2008; De Leo et al., 2005; 
Kessler et al., 1999, 2005; Scocco et al., 2008).  In general, these estimates are highest for 
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women, young and very old age-cohorts, clinical populations with psychiatric disorders, and 
Western, high-income Anglo-culture countries.  Three major cross-sectional surveys, the 
National Comorbidity Study, Part Two (NCS-II) (Kessler et al., 1999), the European Study of the 
Epidemiology of Mental Disorders (ESEMED) (Bernal et al., 2007; Scocco et al., 2008), and the 
World Mental Health Survey (WMH) (Nock et al., 2008a), highlight the cross-national variance 
in estimates of suicidal ideation and consistency in risk factors for suicidal ideation. 
The NCS-II, a cross-sectional survey of the general population in the United States 
during 1990 to 1992, estimates the national lifetime prevalence of ideation to be 13.5% and 
ideation with plan to be 3.9%.  In the survey, interviewers asked individuals, “Have you ever 
seriously thought about committing suicide?” and “Have you ever made a plan for committing 
suicide?”  NCS-II findings indicated that the highest risk for initial suicidal ideation is around the 
late teens and early twenties.  Higher rates of suicidal ideation were associated with being 
female, previously married, less educated, and diagnosed with at least one mental disorder.  
Additionally, although risk for ideation was significantly higher in the presence versus absence 
of a mood, anxiety, or substance use disorder, risk was significantly elevated and highest for 
mood disorders.   
The ESEMED, a cross-sectional survey of the general population in six European 
countries during 2001 and 2003, estimated the cross-national lifetime prevalence of suicidal 
ideation to be 7.8%, a rate substantially lower than the NCS rate.  The ESEMED assessed 
suicidality in individuals' homes with the computer-adaptive WHO Composite International 
Diagnostic Interview (CIDI).  The CIDI includes, “Have any of these experiences happened to 
you:  You seriously thought about committing suicide?  You committed suicide?”  Similar to the 
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NCS results, higher rates of suicidal ideation were associated with being female, younger, and 
previously married.  Among mental disorders, major depressive disorder followed by generalized 
anxiety disorder, post-traumatic stress disorder, and then alcohol dependence, conferred the 
greatest risk.  Italy and Spain had the lowest frequency of suicidal ideation (3.0% and 4.4%, 
respectively) while France and Germany had the highest (12.4% and 9.8%, respectively).  The 
authors postulate that Italy and Spain’s traditional and conservative societies, in part, explain the 
cross-national differences.  Yet, additional analyzes of the ESEMED Italian data only, 
demonstrated no differences in suicidality by Italian geographic areas (e.g., northern Italy, 
central Italy, etc.), even though these areas differ substantially in socio-cultural variables, health 
services, and climate.  
Finally, the WMH, a cross-sectional survey of the general population of 17 countries, 
estimated the cross-national lifetime prevalence of suicidal ideation to be 9.2%.  To assess 
suicidality, when financially and logistically possible, individuals completed the computer-
adaptive CIDI; otherwise, interviewers read the CIDI questions aloud.  Cross-national risk 
factors for suicidal ideation included being female, younger, and less educated.  Among high-
income countries (e.g., United States, Italy, Japan), mood disorders conferred the greatest risk for 
suicidal ideation while impulse control disorders did among low- or middle-income countries 
(e.g., Mexico, Nigeria, Ukraine).  
Both the WMH and NCS-II assessed the time to transition from ideation to more severe 
forms of suicidality.  Results are strikingly similar.  In the WMH, across all 17 countries 
examined, more than 60% of the progressions from ideation to first attempts occurred within the 
first year of initial onset of ideation.  In the NCS-II, among individuals reporting suicidal 
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ideation, cumulative probabilities were 34% for the transition from ideation to a plan and 26% 
from ideation to an unplanned attempt.  Approximately 90% of unplanned and 60% of planned 
first attempts occurred within the first year after initial onset of suicidal ideation.  Thus, the 
suicidal process can evolve swiftly.  It is important to note, however, that most individuals who 
experience suicidal ideation will not plan or attempt suicide during their lifetime. 
To summarize, multiple variables explain the variance in rates of the lifetime prevalence 
of suicidal ideation, including assessment and sampling techniques.  Based on the NCS-II brief, 
structured interviewer-ratings, 13.5% of adults in the United States experience suicidal ideation 
during their lifetime.  Estimates derived from the ESEMED and WMH structured, computer-
adaptive self-report ratings suggest that Europeans, particularly Italians, have a lower likelihood 
of experiencing suicidal ideation during their lifetime, 7.8% and 3.0%, respectively, compared to 
US Americans.  The NCS-II, ESEMED, and WHM show that risk for suicidal ideation is highly 
elevated among individuals who are female, young, and diagnosed with a mood disorder.  
Furthermore, the WMH and NCS-II results suggest that risk of planning an attempt and making 
an attempt is highest within the first year of onset of suicidal ideation but remains years 
afterwards.  Moreover, for some individuals, the suicidal process may be abrupt or fail to follow 
a continuous progression of increasing severity.  Collectively, these findings suggest that early 
intervention is key and support the importance of understanding whether the MDD-SI phenotype 
is associated with an unfavorable or differential initial response to treatment. 
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2.3 CORRELATES OF SUICIDAL IDEATION 
Despite certain similarities, those who think about suicide, those who develop a plan, those who 
attempt, and those who die from suicide are distinct on a number of characteristics (Brent, 2010; 
Fawcett et al., 2009; Kessler et al., 2005).  Most investigations have focused on the latter groups.  
Nonetheless, researchers have identified a number of variables that are associated with lifetime 
and/or current suicidal ideation in adults.  These include psychiatric disorders and illness 
characteristics, physical health, socio-demographic variables, stressors, and personality and 
psychological dimensions.  To clarify, these correlates of suicidal ideation might be distal or 
proximal, and might be risk factors or warning signs (Brenner et al., 2010).  Risk factors are 
associated with a greater potential for experiencing suicidality, e.g., being female or younger 
(American Association of Suicidology [AAS], 2010).  In contrast, warning signs are person-
specific and are associated with imminent risk of engaging in suicidality or experiencing a 
suicidal crisis, e.g., loss of employment or worsening of severe depression (AAS, 2010).   
First, researchers have found strong associations among suicidal ideation, psychiatric 
disorders, and illness characteristics.  Specifically, mood, substance use, anxiety, and psychotic 
disorders increase vulnerability to suicidal ideation (Conner, Li, Meldrum, Duberstein, & 
Cornwell, 2003; Cottler, Campbell, & Krishna, 2005; Goodwin et al., 2001; Joiner, 2005; 
Kessler et al., 1999, 2005; Lloyd et al., 2007; Michal et al., 2010), and having more than one of 
these disorders confers added risk (Joiner, 2005; Kessler et al., 2005; Nock et al., 2008a; Nock, 
Hwang, Sampson, & Kessler, 2009).  For instance, in the NCS-II sample, approximately 80% of 
individuals endorsing suicidal ideation met criteria for at least one DSM disorder during the 
previous 12-months.  Furthermore, there was a dose-response relationship between the number 
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of disorders and risk for planning or making an attempt, such that each additional disorder 
increased risk.  Major depression was the most common single disorder, and anxiety and mood 
disorders were the most common class of disorders.  Likewise, in another report, using 2004 to 
2005 National Survey on Drug Use and Health data, the Office of Applied Studies, Substance 
Abuse and Mental Health Services Administration (SAMHSA) (Office of Applied Studies, 2006) 
found that, among individuals experiencing a past year major depressive episode, 56.3% thought 
during their worst or most recent episode that it would be better if they were dead (death 
ideation), 40.3% experienced suicidal ideation without a plan, and 14.5% experienced suicidal 
ideation with a plan.   
A number of researchers have found major depression to be the most robust independent 
risk factor for suicidal ideation (Joiner, 2005; Kessler et al., 1999; 2005).  Indeed, the estimates 
of point prevalence of suicidal ideation skyrockets to between 47% and 69% in clinical 
populations experiencing a major depressive episode (Sokero, 2006; Sokero et al., 2003).   In 
addition, researchers have documented that specific features of major depression are additive to 
risk, including early age of first depression onset (Lynch et al., 1999), depression severity 
(Goldney et al., 2000), episode chronicity or treatment resistance (Buddeberg, Buddeberg-
Fischer, Gnam, & Schmid, 1996; Papakostas et al., 2003; Pompili et al., 2010), and, in particular, 
the presence and intensity of hopelessness (Beck, Brown, Berchick, Stewart, & Steer, 1990; 
Beck, Steer, & Brown, 1993; Blankstein, 2007; Sokero et al., 2006; Whisman, Miller, Norman, 
& Keitner, 1995), anxiety (Frank et al., 2002; Cassano et al., 2004; Michal et al., 2010; Sareen et 
al., 2005; Sokero, 2006), and perceived burdensomeness (Joiner, 2005; Russell, Turner, & 
Joiner, 2009; Van Orden, Lynam, Hollar, & Joiner, 2006).  Interestingly, Lynch et al. (1999) 
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documented that the risk conferred by early age of depression onset persisted into late-life.  
Conceivably, it might be that early-life depression opens a pathway through which other risk 
factors emerge, accumulate, and increase susceptibility to suicidal ideation.  
Similarly, researchers have observed that specific psychiatric symptoms and illness 
characteristics amplify liability for suicidal ideation, particularly against the backdrop of major 
depression.  These include sleep disturbances, such as difficulty falling or staying asleep and 
nightmares (Chellappa & Araujo, 2007; Cukrowicz et al., 2006; McCall et al., 2010; Wojnar et 
al., 2009), states of negative arousal, such as anxiety, agitation, irritability, impulsivity, and 
mixed states (Akiskal & Benazzi, 2005; Balazs, Benazzi, Rhimer, Rhimer, & Akiskal, 2006; 
Benazzi, 2004, 2006; Cassano et al., 2004; Dalrymple & Zimmerman, 2007; Fava et al., 2008; 
Goodwin et al., 2001; Olgiati, Serretti, & Colombom, 2006), depersonalization (Michal et al., 
2010; Yoshimasu et al., 2006), psychosis (Cassano et al., 2004; Kessler et al., 1999), and 
syndromal or subsyndromal bipolarity (Angst, Gamma et al., 2003; Balestrieri et al., 2006; 
Benazzi, 2004, 2006; Maremmani et al., 2007).  Additionally, alcohol or substance use (De Leo 
et al., 2005; Kessler et al., 1999, 2005; Pompili et al., 2010) and any anxiety (Michal et al., 2010; 
Sareen et al., 2005), independent or concurrent with these symptoms, increase risk.  For instance, 
SAMHSA (Office of Applied Studies, 2006) reported that individuals experiencing past year 
major depression who also reported past month binge alcohol or illicit drug use were more likely 
to report suicidal ideation (61.8% and 67.0%, respectively) than were individuals with past year 
major depression but no alcohol or substance use (57.1% and 56.9%, respectively).  They also 
noted that individuals experiencing a past year substance use disorder were more than three times 
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as likely to have seriously considered suicide compared to those without a substance use 
disorder.   
Second, apart from mental health, researchers have found strong associations between 
poor or unstable physical health and suicidal ideation, particularly among males (Alexopoulos et 
al., 2009; Kessler, Ormel, Demler, & Stang, 2003b; Legleye, Beck, Peretti-Watel, Chau, & 
Firdion, 2010).  These factors include presence of physical disability and functional impairment 
(Duberstein, Conwell, Conner, Eberly, & Caine, 2004; Russell, Turner, & Joiner, 2009), chronic 
pain (Edwards, Smith, Kudel, & Haythornthwaite, 2006; Fishbain, Bruns, Disorbio, & Lewis, 
2009; Scott et al., 2010), and any medical comorbidity (De Leo et al., 2005; Goldney, Fisher, 
Wilson, & Cheok, 2001; Rollman & Shear, 2003).  Remarkably, simply reporting poor physical 
health, irrespective of actual health status, and low quality of life seems to increase liability 
(Dennis, 2007; Goodwin et al., 2001; Goodwin & Olfson, 2002).  Russell, Turner, and Joiner 
(2009) postulate that the contribution of these variables to increased risk of suicidal ideation 
might be that poor health or physical disability increases perceptions of burdensomeness and/or 
feelings of isolation.  Of note, some researchers have demonstrated that elevated body mass 
index (BMI) and obesity increase risk for suicidal ideation (Carpenter, Hasin, Allison, & Faith, 
2000; Fagiolini et al., 2004; Mather, Cox, Enns, & Sareen, 2009), whereas others have reported it 
protects against risk (Goldney et al., 2009). 
Third, researchers have consistently reported elevated rates of suicidal ideation in the 
young and very old, women, individuals with low education, individuals lacking stable 
relationships, social support, or employment, and individuals in low socio-economic brackets 
(De Leo et al., 2005; Dennis, 2007; Gunnell et al., 2004; Hintikka et al., 2001a, 2001b; Kessler et 
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al., 2005; Legleye et al., 2010; McMillan, Enns, Asmundson, & Sareen, 2010; Michal et al., 
2010; Nock et al., 2008a, 2009; Scocco et al., 2008; Sokero et al., 2003).  Notably, these risk 
factors seem to be consistent cross-nationally (Nock et al., 2008a).  Some evidence supports 
gender differences for a few of these factors.  For example, males seem to be at greater risk than 
are females for developing suicidal ideation following the dissolution of a relationship (Kõlves, 
Ide, & De Leo, 2010) or employment (Legleye et al., 2010).   
Fourth, researchers have consistently reported elevated rates of suicidal ideation among 
individuals with recent or lifetime histories of stressful or negative life events (Fanous, Prescott, 
& Kendler, 2004; Goldney et al., 2000; Hirsch, 2007; Marshall et al., 2001; Nock et al., 2008a, 
2009; Weissman et al., 1999).  These independent and robust predictors of suicidal ideation 
include family and romantic conflict (De Leo et al., 2005; Goldney et al., 2000; Konick & 
Gutierrez, 2005; Meneese & Yutrzenka, 1990), death of a loved one or child (Qin & Mortensen, 
2007), loss of employment or income (Hintikka et al., 2001a, 2001b; McMillan et al., 2010; 
Michal et al., 2010; Turvey, Stromquist, Kelly, Zwerling, & Merchant, 2002), and legal or 
disciplinary problems (De Leo et al., 2005).  Especially deleterious stressors include poor 
perinatal conditions, child maltreatment or abuse (Afifi, Boman, Fleisher, & Sareen, 2009; De 
Leo et al., 2005; Joiner et al., 2007; Silverman, Reinherz, & Giaconia, 1996), sexual abuse 
(Talbot, Duberstein, Cox, Denning, & Conwell, 2004), domestic violence (Afifi et al., 2009), and 
chronic stress, including frequent exposure to painful and provocative stimuli (Smith & 
Cukrowicz, 2010; Joiner, 2005).  Nock and colleagues (2008a) suggest that, consistent with 
diathesis-stress models of suicidality, stress and negative life events might interact with other risk 
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factors, such that these events increase risk among individuals already predisposed to suicidality.  
Yet, it is unclear through which mechanisms these factors might increase susceptibility.   
Another stressor that appears to predispose an individual to suicidal ideation is exposure 
to suicidality, including parental suicidal ideation (Goodwin, Beautrais, & Fergusson, 2004) or 
attempt (Lieb, Bronisch, Hofler, Schreier, & Wittchen, 2005), personal history of suicide attempt 
(Jamison, 1999; Joiner, 2005), and knowing anyone who attempted or completed suicide (De 
Leo et al., 2005).  Importantly, although family studies provide evidence for a heritable risk of 
suicidal behavior, thus far, familial transmission of liability for suicidal ideation appears best 
explained by the risk associated with psychiatric disorders (Brent, 2010).   
Finally, a number of researchers have suggested that certain personality and 
psychological dimensions contribute to an individual’s vulnerability for developing suicidal 
ideation.  These include Axis II pathology (McGirr et al., 2009; Starcevic, Bogojevic, 
Marinkovic, & Kelin, 1999), low self-esteem (Bhar, Ghahramanlou-Holloway, Brown, & Beck, 
2008), low self-directedness and high self-transcendence (Conrad et al., 2009), high levels of 
neuroticism/negative emotionality and self-criticism (Beck, Steer, & Brown, 1993; Cox, Enns, & 
Clara, 2004), perfectionism (Blankstein, 2007; O’Connor & Forgan, 2007), cyclothymic 
temperament (Kochman et al., 2005), and depressogenic thinking (Smith et al., 2006).  To 
clarify, self-esteem includes beliefs about oneself and beliefs about how other people regard 
oneself.  Self-directedness refers to self-efficacy and a conviction of being able to positively 
influence a situation or solve a problem.  Self-transcendence incorporates spirituality and 
creativity, and depressogenic thinking comprises dysfunctional attitudes, pessimism, and 
negative inferential styles.  Notably, Bhar, Ghahramanlou-Holloway, Brown, and Beck (2008) 
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documented that low self-esteem added to the risk for suicidal ideation even after controlling for 
depression and hopelessness.  Also of note, Cox, Ennis, and Clara (2004) found a significant 
association between neuroticism and ideation but not between neuroticism and attempts.  They 
submit that some psychological dimensions, including neuroticism, might establish vulnerability 
to suicidal ideation and, in turn, suicidal ideation opens susceptibility to suicidal behaviors. 
 To summarize, a number of psychiatric disorders and symptoms, physical health factors, 
socio-demographic variables, stressful or negative life events, and personality and psychological 
dimensions distinguish individuals who experience suicidal ideation from those who do not 
experience suicidal ideation and from those who engage in suicidal behaviors.  Major depression 
appears to be at least one of the major gateways through which suicidal ideation functions.  
Major depression can be both a distal and proximal risk factor, and a warning sign.  On one 
hand, suicidal ideation might be the sequelae of major depression.  On the other hand, major 
depression might open a pathway through which other risk factors surface, increasing an 
individual’s susceptibility to suicidal ideation.  Considering the nature of suicidal ideation, 
efficient and effective treatment for MDD-SI is key – and might be one way to prevent the 
transition from suicidal ideation to suicidal behaviors.   
2.4 SUICIDAL IDEATION AND TREATMENT 
Previous or chronic experiences with suicidal ideation might wear on an individual such that he 
or she slowly or quickly transitions from experiencing suicidal ideation to engaging in suicidal 
behaviors (Joiner, 2005; Kessler et al., 2005).  Hence, there is an urgency to optimize the first-
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line treatment of MDD-SI and, in turn, reduce time to recovery.  Yet, to date, the literature is 
relatively uninformative about whether first-line treatments for MDD-SI and MDD should be the 
same, and whether psychotherapy or antidepressant pharmacotherapy is a preferable initial 
treatment strategy for MDD-SI (Baldessarini et al., 2007; Pompili et al., 2010; Szanto et al., 
2003).  There is some evidence, however, to indicate that MDD-SI is responsive to targeted 
treatment (Alexopoulos et al., 2009; Zisook et al., 2009), but that the effect is less than that 
which is observed in the absence of suicidal ideation.  Conceivably, this finding may be 
explained by the fact that many of the variables correlated with an unfavorable response to 
treatment also are associated with suicidal ideation.  
First, there is evidence that suicidal ideation remits with antidepressant pharmacotherapy 
(Mulder, Joyce, Frampton, & Luty, 2008; Tondo, Lepri, & Baldessarini, 2008; Zisook et al., 
2009) and combined antidepressant pharmacotherapy and psychosocial treatment (Szanto et al., 
2001, 2003).  For example, in a secondary analysis of data from the Sequenced Treatment 
Alternatives to Relieve Depression (STAR*D) study, Zisook et al. (2009), report that among 
1,738 individuals with baseline suicidal ideation (indicated by a score of one or greater on the 
QIDS item 12, where 1 = life empty or not worth living), 74% experienced improvement in 
suicidal ideation and depressive symptoms following 12 to 14 weeks of antidepressant 
pharmacotherapy (citalopram).  Importantly, they found that reduction of suicidal ideation was 
strongly related to overall response and remission of depressive symptoms.  Specifically, 
individuals with MDD-SI who did not experience a response or remission with treatment were 
significantly more likely to report suicidal ideation post-treatment than were individuals with 
MDD-SI who did experience a response or remission.  In another study, Alexopoulos and 
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colleagues (2009) demonstrated that care management reduces suicidal ideation (defined as 
present or not presented with the SSI) and depressive symptoms more than does usual treatment 
among primary care patients, aged sixty or older, experiencing major or minor depression.  
Specifically, care managers helped detect depression, offered algorithm-based recommendations, 
monitored symptoms and medication side-effects, conducted interpersonal psychotherapy with 
individuals who refused medication, and provided follow-up.  At four months, suicidal ideation 
had declined by 12.8% in the care management group compared with 3.0% in the usual care 
group; this was the sharpest decline during the study.  At eight and twelve months, the rates of 
suicidal ideation were similar between groups.  At twenty-four months, suicidal ideation had 
declined 18.4% in the care management group compared to 8.3% in the usual care group.  
Notably, at twenty-four months, 11.4% of the care management group (a decline of 18.3% from 
baseline) and 12.1% of the usual care group (a decline of 8.3% from baseline) continued to 
experience death or suicidal ideation.   
Surprisingly, although there were reports documenting the effect of antidepressant 
pharmacotherapy, with or without an adjunctive psychosocial intervention, we were able to find 
only one investigation of the efficacy of psychotherapy as a monotherapy for suicidal ideation in 
the absence of self-injurious or suicidal behaviors (Heisel et al., 2009).  In this pilot study, Heisel 
and colleagues (2009) assessed the feasibility, tolerability, and acceptability of a 16-week course 
of interpersonal psychotherapy adapted for 12 older adults experiencing MDD-SI.  Heisel and 
colleagues assessed suicidal ideation with the self-report Geriatric Suicide Ideation Scale (Heisel 
& Flett, 2006) and clinician-administered SSI.  Preliminary findings demonstrated that the 
intervention was efficacious for reducing suicidal ideation and depressive symptoms but 
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insufficient to bring about a complete remission of depressive symptoms; average post-treatment 
HRSD scores remained high (M = 12.8, SD = 7.6).  
Second, there is some preliminary evidence to suggest that MDD-SI and MDD might be 
associated with different treatment needs (Szanto et al., 2001) and treatment response trajectories 
(Pompili et al., 2010; Szanto et al., 2003).  For example, in one study, Szanto et al. (2001) 
compared treatment needs and remission rates among elderly individuals with MDD-SI to those 
with MDD.  Szanto and colleagues classified individuals as experiencing MDD-SI if they scored 
a two or higher on the Question 3 of the HRSD.  Both groups received acute and continuation 
treatment with combined interpersonal psychotherapy and antidepressant pharmacotherapy 
(nortriptyline).  Remission rates between the MDD-SI and MDD groups were nearly identical, 
77% versus 78%, respectively.  The MDD-SI group, however, was more likely to need 
augmentation pharmacotherapy (e.g., lorazepam for anxiety or insomnia, lithium or paroxetine as 
augmentation, or perphenazine for severe agitation) than was the MDD group, 43% versus 23%, 
respectively.  Essentially, the MDD-SI group needed “more” than did the MDD group to achieve 
remission.  In a secondary analysis of this data, combined with data from two other late-life 
depression treatment trials, Szanto and colleagues (2003) investigated the course of suicidal 
ideation and treatment response during the first twelve weeks of treatment among three groups: a 
high-risk group (recent attempt or current suicidal ideation, HRSD Question 3 score > 3; n = 45), 
a moderate-risk group (recurrent thoughts of death, HRSD Question 3 score = 2; n = 284), and a 
low-risk group (none of the above, HRSD Question 3 score < 1; n = 65).  By week twelve of 
treatment, suicidal ideation had resolved among all individuals, and only 4.6% continued to 
experience thoughts of death.  Median time to response, however, was significantly longer in the 
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high-risk group (6 weeks) and moderate-risk group (5 weeks) compared to the low-risk group (3 
weeks).  Moreover, compared to individuals in the moderate- and low-risk groups, individuals in 
the high-risk group were significantly less likely to be full responders at week twelve.  Thus, 
whereas suicidal ideation in late-life depression rapidly resolved with antidepressant 
pharmacotherapy or antidepressant pharmacotherapy and psychotherapy, depressive symptoms 
did not.  Specifically, compared to individuals with MDD, individuals with MDD-SI or suicidal 
behavior needed “longer” to experience relief from depressive symptoms.  Likewise, in another 
study, Pompili and colleagues (2010) specifically addressed the question of whether MDD-SI 
was associated with an unfavorable response to intravenous antidepressant treatment 
(citalopram) by comparing treatment response among 82 individuals with major depression and a 
unipolar or bipolar diagnosis, with or without suicidality (ideation or behaviors) at intake to 
treatment.  An HRSD Question 3 score greater than or equal to three indicated presence of 
suicidality.  Of note, all individuals were eligible for intravenous antidepressant treatment 
because they had failed to respond to at least one month of standard oral antidepressant 
treatment.  Individuals with suicidality were more likely than were individuals without 
suicidality to have been ill longer, have lifetime substance abuse, have received a mood 
stabilizer, and be young and unmarried.  At intake to treatment, depression severity between the 
two groups was nearly identical; however, after six weeks of treatment, compared to individuals 
without suicidality, individuals with suicidality improved only 46.6% as much and were less 
likely to experience at least a 20% improvement in symptoms, 57% versus 26%, respectively.  
Furthermore, despite experiencing reductions in overall depression severity and suicidality, 
individuals’ suicidality ratings remained elevated at six weeks of treatment.  Finally, in logistic 
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regression analyses, suicidality was the only factor among many (e.g., depression severity, 
substance use history) to be significantly associated with a less favorable treatment response.  
Pompili and colleagues argue that since the groups did not differ in depression severity at intake, 
greater depression severity cannot easily explain the inferior treatment response associated with 
suicidality.  Rather, they assert that something associated with or part of the phenotype is 
accounting for the variance in treatment response.   
Of note, a major limitation of the aforementioned investigations is the grouping of 
individuals with suicidal ideation and suicidal behaviors.  Again, preliminary investigations 
indicate that those who experience suicidal ideation are distinct from those who engage in 
suicidal behaviors (Brent, 2010; Kessler et al., 2005).  
Third, and complicating speculation about MDD-SI and initial treatment response even 
further, is the indirect evidence supporting both a differential response favoring psychotherapy 
and favoring pharmacotherapy.  For example, on one hand, some of the factors identified as 
presumably predictive of poorer treatment response to psychotherapy for major depression also 
are associated with suicidal ideation.  These include early age of illness onset (Klein et al., 1999), 
psychotic features (Berlanga, Heinze, Torres, Apiquian, & Caballero, 1999; Moller, 1994; 
Mueller et al., 1999; Volz, Muller, Sturm, Preussler, & Moller, 1995), and neuroticism (Berlanga 
et al., 1999; Joyce et al., 2007; Luty et al., 2007; Nelson & Cloninger, 1997).   
On the other hand, some of the factors identified as presumably predictive of poorer 
treatment response to antidepressant pharmacotherapy for major depression also are associated 
with suicidal ideation.  These include undiagnosed or subthreshold bipolarity (Akiskal & 
Benazzi, 2005; Akiskal, Benazzi, Perugi, & Rhimer, 2005; Baldessarini et al., 2007), “anxious” 
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depression (Fava et al., 2008), high social dysfunction (Sotsky et al., 1991), being unemployed 
(Fournier et al., 2009), and having a greater number of recent life events (Fournier et al., 2009).  
Then again, some of the factors associated with suicidal ideation are predictive of poorer 
response to both psychotherapy and pharmacotherapy.  These include severe or chronic major 
depressions (Fournier et al., 2010; Frank, Novick, & Kupfer, 2005; Judd et al., 1998; Mueller et 
al., 1999), medical comorbidities (Iosifescu, 2007), alcohol use (Klein et al., 1999; Worthington 
et al., 1996), anxiety (Fawcett et al., 1990; Feske, Frank, Kupfer, Shear, & Weaver, 1998; Frank 
et al., 2000, 2010), and personality pathology (Cyranowski et al., 2004; Frank et al., 2005; Thase, 
1996). 
To summarize, the extant literature is inconclusive about the relationship between MDD-
SI and treatment.  One, although there is evidence indicating MDD-SI is responsive to 
antidepressant pharmacotherapy, there is a paucity of research on the efficacy of psychosocial 
monotherapies for MDD-SI.  Hence, it is premature to speculate whether psychotherapy or 
antidepressant pharmacotherapy is a preferable initial treatment strategy for MDD-SI.  Two, 
while there is evidence demonstrating that MDD-SI and MDD have different treatment needs 
and response curves, this work is preliminary.  Moreover, it has questionable generalizability 
since researchers often grouped individuals with suicidal ideation and suicidal behaviors. Finally, 
while there is evidence indicating that some of the predictors of suicidal ideation also are robust 
predictors of an unfavorable response to antidepressant pharmacotherapy, these predictors also 
are associated with an unfavorable response to psychotherapy.  Consequently, one could 
hypothesize that either (or neither) treatment might be the best first-line initial treatment strategy 
for MDD-SI.  Taken together, findings from the current literature are promising, and suggestive 
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of future avenues for exploration.  What remains unresolved, however, is what feature, or cluster 
of features, associated with MDD-SI explains between group variance.  One explanation might 
be subsyndromal and syndromal mood and anxiety comorbidity.    
2.5 SUBSYNDROMAL ANXIETY AND MOOD SYMPTOMS  
Based on the literature, it is important to assess a broad array of lifetime and concurrent anxiety 
and mood symptomatologies potentially associated with MDD-SI.  First, co-occurrence of major 
depression, both with other Axis I disorders and with Axis II disorders, appears to be the rule.  It 
has long been acknowledged that these comorbidities at a syndromal level make depression 
difficult to treat because they complicate and prolong the treatment process (Cyranowski et al., 
2004; Feske et al., 1998; Frank et al., 2000).  Yet, investigators also have demonstrated negative 
effects of comorbidity at the subsyndromal level.  For example, among individuals with recurrent 
major depression, Frank and colleagues (2000) reported that while only 18% met criteria for 
lifetime panic disorder, 37.7% experienced subsyndromal anxiety.  Compared to individuals 
without, individuals with subsyndromal anxiety were significantly less likely to respond to 
monotherapy with interpersonal psychotherapy and more likely to experience a delay in time to 
full remission with combination interpersonal psychotherapy and antidepressant 
pharmacotherapy (18.1 weeks versus 10.3 weeks, respectively).  Similarly, Feske, Frank, Kupfer, 
Shear, & Weaver (1998) found that women with recurrent major depression and a lifetime 
history of panic and somatic anxiety symptoms were less likely to respond to interpersonal 
psychotherapy than were women with major depression without these panic features.  Overall, 
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the presence of subsyndromal or syndromal anxiety is associated with more severe symptom 
profiles, including greater depression severity and higher rates of suicidality, poorer psychosocial 
functioning and quality of life, and less favorable outcomes to pharmacotherapy and 
psychotherapy,  (Benvenuti et al., 2010; Frank et al., 2000; Michal et al., 2010).  
Second, it is important to explore a broad array of lifetime and concurrent mood 
symptoms potentially associated with MDD-SI because the unipolar-bipolar dichotomy, as 
represented in DSM-IV-TR, is a simplification of clinical reality.  Indeed, some individuals with 
“unipolar” disorders experience “bipolar” symptoms.  For these individuals, their mood disorders 
exist along a continuum of affective pathology that cannot be parsed into two discrete mood 
states (Akiskal & Benazzi, 2005; Akiskal et al., 2005; Angst et al., 2003; Balestrieri et al., 2006; 
Cassano et al., 2004, 2009).  Importantly, these subtle features may contribute to suicidality.  For 
instance, investigators have demonstrated strong associations among subsyndromal hypomanic 
symptoms and suicidal ideation (Cassano et al., 2004, 2009, 2010; Frank et al., 2000; Wildes, 
Marcus, Gaskill, & Ringham, 2007).  In one study, Cassano et al. (2004) found that individuals 
with recurrent unipolar disorder reported a significant number of subsyndromal hypomanic and 
manic symptoms, and that the more of these items they endorsed, the greater the likelihood of 
reporting suicidal ideation.  In another study, Balestrieri et al. (2006) found that the greater the 
number and type of depressive and manic-hypomanic symptoms endorsed, the greater the 
incidence of suicidality among individuals with a psychiatric illness (schizophrenia, borderline 
personality disorder, bipolar disorder, unipolar depression, or panic disorder) and in a 
comparison group of healthy controls.  
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To summarize, major depression often co-occurs with anixety and other mood features. 
Importantly, these conditions negatively impact response to psychological and pharmacological 
interventions.  Yet, most – if not all – investigations of MDD-SI fail to assess both syndromal 
and subsyndromal anxiety and mood conditions.  Consequentially, the delineated MDD-SI 
phenotype is artificially restricted.  Thus, a first step to increasing our understanding of MDD-SI 
might be developing a rich clinical phenotype of MDD-SI that includes lifetime and concurrent 
mood and anxiety symptomatologies.  To this end, the Spectrum Assessment Method (Cassano 
et al., 1997, 1999, 2004) seems particularly well suited.   
2.6 THE SPECTRUM ASSESSMENT METHOD 
The Spectrum Assessment Method is a reliable and valid way to document the phenomenology 
and clinical phenotype of MDD-SI (Cassano et al., 1997, 1999, 2004; Fagiolini et al., 1999).  
This method is a dimensional approach to describing psychopathology that produces clinical 
phenotypes characterized by a broad array of manifestations of the target disorder, including its 
core and most severe symptoms, as well as a range of more subtle features related to the core 
condition, including prodromal, early-onset, attenuated, trait-like, and residual symptoms.  
Indeed, Cassano and the Pittsburgh-Pisa Spectrum Collaborative Project Group developed the 
spectrum assessments, in part, as a way to investigate the continuum between the criterion 
symptoms of each disorder and the sub-threshold symptomatology which precede, follow, or are 
manifested in concurrence with the main disorder.  They assert that these “spectrum conditions” 
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have important implications for illness course and treatment outcomes (Benvenuti et al., 2010; 
Cassano et al., 2009; Frank et al., 2000, 2010). 
Of particular interest to this investigation are both the mood and panic-agoraphobic 
spectrum conditions, as assessed by the lifetime and past month versions of the Mood Spectrum, 
Self-Report (MOODS) and Panic-Agoraphobic Spectrum, Self-Report (PAS) instruments, 
respectively.  Both questionnaires were developed simultaneously in English and Italian, and 
based on corresponding structured clinical interviews.  Cassano and colleagues have 
demonstrated that the MOODS and PAS are reliable and have good-to-outstanding psychometric 
properties (Rucci & Maser, 2000).   
The MOODS was designed to evaluate the lifetime and past month presence or absence 
of the full range of mood pathology an individual may experience including DSM-IV core 
symptoms of depression, hypomania and mania, atypical symptoms, subthreshold 
manifestations, and behavioral traits and lifestyles that arise as a means of coping with mood 
symptoms (Cassano et al., 2004; Dell'Osso et al., 2002; Fagiolini et al., 1999).  In general, the 
MOODS attempts to characterize the “temperamental” affective dysregulation present 
throughout an individual’s lifetime or recent affective episode.  
Specifically, the MOODS is a self-report instrument that asks the individual to answer 
“Yes” or “No” to 161 items coded as present or absent for one or more periods of at least three to 
five days during an individual’s lifetime (MOODS-Lifetime) or past month (MOODS-PM).  For 
some questions, such as those exploring temperamental features or specific events, the duration 
is not specified because it would not be applicable.  Items are organized into three manic-
hypomanic and three depressive domains exploring mood, energy, and cognition, plus a domain 
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that explores disturbances in rhythmicity and vegetative functions.  Fifteen factors have been 
identified with exploratory factor analysis (Cassano et al., 2009, 2010).  These factors, and the 
feature or core domain(s) of assessment are: (1) depressive mood: core symptoms of depression, 
anhedonia, and temperamental features; (2) psychomotor retardation: contra-polar features of 
mania, retardation in different areas of daily activities, physical weakness, and tiredness; (3) 
suicidality: ideation, planning, and severity of attempts; (4) drug or illness related depression: 
mood dysregulation during common physical illness and/or following medication or substance 
use; (5) psychotic features: paranoid thoughts and psychotic features; (6) neurovegetative 
symptoms: rhythm disruption, problems with sleep, appetite, and sexual functioning; (7) 
psychomotor activation: core symptoms of mania; (8) creativity: bursts of artistic creativity and 
sensitivity; (9) mixed instability: instability in mood, work, friendships, and personal 
relationships; (10) sociability/extraversion: optimism, sociability, and extraversion; (11)  
spirituality/mysticism: ecstatic experiences and heightened sense of reality; (12) mixed 
irritability: mood dysregulation, hostility, and irritability during common physical illness and/or 
following medication or substance use; (13) inflated self-esteem: grandiose self-esteem; (14) 
euphoria: euphoric mood elevation of pure mania or “sunny” hypomania; and (15) recklessness: 
engagement in risky behaviors. Of particular interest, the suicidality factor provides information 
about the suicidal process, such that it provides information across the suicidality continuum, 
assessing experiences of death wishes and passive ideation, attempt planning, attempt, and need 
for medical attention following attempt (Cassano et al., 2009). 
The PAS was designed to evaluate the lifetime and past month presence or absence of a 
broad array of manifestations of panic disorder including DSM-IV core symptoms of panic, 
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subthreshold manifestations, and behavioral traits that arise as a means of coping with anxiety 
symptoms.  The PAS is a self-report instrument that asks the individual to answer “Yes” or “No” 
to 114 items as present or absent.  Items fall into one of ten factors.  These factors, and the 
feature or core domain(s) of assessment are:   (1) panic symptoms: somatic symptoms of panic 
attacks; (2) separation anxiety: uneasiness when sleeping alone or away from home and fearful 
of harm coming to family members; (3) agoraphobia: avoidance behaviors related to fear of 
panic; (4) medical reassurance: excessive requests for test, calls to doctor, and use of emergency 
services; (5) rescue object: magical ideas about the “protective” power of specific objects; (6) 
depersonalization: sense of detachment from one’s own being and a sense of unreality; (7) family 
reassurance:  excessive help-seeking from family, friends, and neighbors; (8) drug phobia: 
reluctance to ingest substances (e.g., caffeinated beverage, psychotropic medication) and 
sensitivity to effects; (9) claustrophobia: uneasiness in situations that can be broadly 
characterized as evoking suffocation or entrapment fears; and (10) loss sensitivity: excessive 
difficulty with ending relationships. 
To summarize, the Spectrum Assessment Method is a dimensional approach to 
psychopathology and produces clinical phenotypes characterized by a broad array of overt and 
subtle prodromal, subsyndromal, and syndromal manifestations of the target disorder.  Assessing 
the mood and panic-agoraphobic spectrum conditions in MDD-SI may produce a more full 
clinical phenotype and, subsequently, lead to a more refined understanding of the illness and 
treatment needs.  
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2.7 HYPOTHESES 
Based on the literature to date, we hypothesized that among a group of adults entering treatment 
for unipolar major depression, individuals with baseline suicidal ideation (MDD-SI) and 
individuals without baseline suicidal ideation (MDD) would differ in: 
 
H1 Pre-treatment socio-demographic and baseline clinical characteristics such that individuals 
with MDD-SI would be younger, would be more likely to be female, would be more likely to 
be single or separated, would be more likely to be unemployed, would have lower quality of 
life and satisfaction, would have greater depression severity, would have a greater number of 
previous depressive episodes, and would have higher rates of medical comorbidities and 
obesity, early onset major depressive disorder, comorbid anxiety disorders, alcohol abuse, 
and cigarette smoking.   
 
H2 Lifetime experience of suicidal ideation and suicidal behavior, such that individuals with 
MDD-SI would be more likely to report a history of suicidal ideation and previous suicide 
attempts.  
 
H3 Lifetime and past month spectrum assessment scores such that individuals with  
     MDD-SI would have higher:  
  H3A  Lifetime and past month Mood Spectrum – Self-Report (MOODS)  
          total scores and higher lifetime and past month depressive mood,  
  neurovegetative symptoms, spirituality, and recklessness factor scores; and 
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  H3B   Lifetime and past month Panic-Agoraphobic Spectrum – Self-Report  
          (PAS) total scores and higher lifetime and past month panic  
          symptoms and depersonalization factor scores.   
 
H4 Depression severity after six weeks of monotherapy, such that individuals with MDD-SI 
would have greater depression severity, as evidenced by higher adjusted Hamilton Rating 
Scale for Depression, 25-item (HRSD-25-A) total scores at week seven1
 
.  Furthermore, 
suicidal ideation would not be associated with a differential treatment response to SSRI or 
IPT.  Accordingly, suicidal ideation would be a non-specific predictor of initial treatment 
response because it is a pre-treatment characteristic that has a main effect but no interactive 
effect on initial treatment response. 
To test these hypotheses, we completed a secondary analysis of data from a two-site, cross-
national clinical trial in which individuals presenting for treatment of a non-psychotic unipolar 
major depressive episode were randomly allocated to a treatment protocol involving SSRI, IPT, 
and, in the absence of a response or sustained remission, their combination. 
                                                 
1 HRSD-25-A total scores are HRSD-25 total scores minus the score on the suicide item. 
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3.0  METHODS 
This investigation was a secondary analysis of data from the pilot and full depression phenotypes 
studies (MH65376), directed by Drs. Ellen Frank and Giovanni B. Cassano, conducted between 
2003 and 2008 at outpatient research clinics associated with the Departments of Psychiatry at the 
University of Pittsburgh, Pennsylvania, United States of America and University of Pisa, Italy.  
In the depression phenotypes studies, participants were treated with acute and continuation 
protocol pharmacotherapy with the SSRI antidepressant citalopram (pilot study at Pisa) or 
escitalopram (pilot study at Pittsburgh; full study at both sites), protocol psychotherapy with 
interpersonal psychotherapy (IPT), and, in absence of a response or remission, their combination 
(IPT/SSRI or SSRI/IPT).  The ultimate goal of the depression phenotype studies was to define 
clinically useful and specific profiles of participants who would benefit from pharmacotherapy 
versus psychotherapy and of those who would require treatment augmentation.  Notably, the 
pilot and full study were identical except with regard to psychotropic agent; escitalopram was not 
available in Europe during the pilot study period.  To avoid confusion and redundancy, from this 
point forward, we reference the pilot and full depression phenotype studies as one study. 
The University of Pittsburgh’s Biomedical Institutional Review Board (IRB) and the 
Ethics Committee of the Azienda Ospedaliero-Universitaria of Pisa approved all recruitment, 
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assessment, and treatment procedures.  All participants provided written informed consent after 
receiving a complete description of the study and having an opportunity to ask questions.  
3.1 PARTICIPANTS 
The sample for this report comprised 368 male and female adult outpatients experiencing a non-
psychotic unipolar major depressive episode (MDE).  Participants were recruited from the 
outpatient mental health clinics of Western Psychiatric Institute and Clinic (Pittsburgh, PA) and 
the University of Pisa (Pisa, Italy).   
To enter the study, participants were required to be between 18 and 64 years of age with a 
current, index episode of non-psychotic unipolar major depression, as defined by the Diagnostic 
and Statistical Manual for Mental Disorder, Fourth Edition (DSM-IV) (American Psychiatric 
Association [APA], 2000), and determined by the Structured Clinical Interview for Axis I DSM-
IV Disorders (SCID-I) (First, Gibbon, Spitzer, & Williams, 2001).  The index MDE was required 
to meet minimum severity criteria, defined as a score of 15 or greater on the 17-item Hamilton 
Rating Scale for Depression (HRSD-17; Hamilton, 1960).  Diagnostic exclusion criteria were (a) 
history of manic or hypomanic episode(s), (b) history of schizophrenia or schizoaffective 
disorder, (c) organic affective syndrome, (d) current psychosis, (e) current primary diagnosis of 
anorexia nervosa or bulimia nervosa, (f) drug or alcohol abuse/dependence within the past three 
months, and (g) satisfying full criteria for antisocial personality disorder, as determined by the 
Structured Clinical Interview for Axis II DSM-IV Disorders (SCID-II) (First, Gibbon, Spitzer, & 
Williams, 1996).  No other Axis I or II disorder constituted exclusion.  Treatment and medical 
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exclusion criteria were (a) well-established, well-documented history of intolerance or non-
response to one or more of the study treatments, (b) pregnancy or breastfeeding, (c) unable or 
unwilling to provide informed consent, and (d) specific medical exclusions.  Medical exclusions 
included (a) index episode was a secondary effect of medically prescribed drugs, (b) presence of 
uncontrolled medical illness, and (c) concomitant psychotropic medications (with the exception 
of low-dose benzodiazepines, permitted only in participants who could not be fully withdrawn) 
or over-the-counter and herbal therapies.  
Participants with current suicidal ideation or behaviors were not excluded if, in the 
treatment team’s judgment, the suicidality could be managed on an outpatient basis.  Participants 
who required inpatient treatment because of suicide risk were excluded or discontinued from the 
study and referred to an inpatient mood disorder unit, voluntarily or, if required, involuntarily.   
3.2 PROCEDURE 
Of relevance to the aims and hypotheses of this secondary investigation is only the first six 
weeks of the protocol, including treatment and assessment.  Therefore, the complete study design 
and treatment algorithm is only briefly described (for a full description, see Frank et al., 2010). 
3.2.1 Overview of study design 
Participants were randomly allocated (with simple randomization) to an initial treatment strategy 
of SSRI or IPT.  Participants received augmentation with the other treatment if the initial 
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treatment strategy was unsuccessful in bringing about a response within six weeks of treatment 
or stabilization within twelve weeks of treatment.  We defined response as a fifty percent 
reduction in baseline HRS-D-25 scores and stabilization as three consecutive weeks during 
which the HRS-D-17 score was equal to or averaged seven (Frank et al., 1991).  If the treatment 
team deemed it clinically necessary, deviations from the algorithm were permitted such that 
participants could receive acute treatment augmentation earlier than week seven.  Participants 
remained in weekly acute treatment for at least twelve weeks and, if applicable, ten sessions of 
IPT.  Once participants achieved stabilization and minimum acute treatment criteria, they entered 
the continuation phase and maintained their acute treatment regimen for six months.  If 
participants failed to meet criteria for stabilization with sixty-four weeks of acute treatment, they 
were terminated from the study and referred to other treatment.  
3.2.2 Initial treatment strategies 
Participants allocated to an initial treatment strategy of pharmacotherapy were seen by 
experienced psychopharmacologists for weekly 20 to 30 minute visits.  Citalopram (pilot study at 
Pisa) was started at 20 mg/day and titrated up or down as needed, with the aim of achieving 
symptom stabilization and/or a dose of 40 mg/day.  Escitalopram (pilot study at Pittsburgh; full 
study at both sites) was started at 10 mg/day and titrated up or down as needed, with the aim of 
achieving symptom stabilization and/or a dose of 20 mg/day.  Maximum permissible dose was 
60 mg/day for citalopram and 40 mg/day for escitalopram.  After six weeks of treatment, those 
participants initially allocated to SSRI who had achieved the targeted dose and had not evidence 
a response began treatment augmentation with IPT.  Of note, escitalopram is an enantiomer of 
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citalopram; therefore, escitalopram and citalopram are similar psychotropic agents.  Escitalopram 
is marketed as an enhanced citalopram.  Escitalopram was not available in Europe during the 
pilot study period.  Therefore, pilot study participants treated at the Pisa site received citalopram.  
All full study participants received escitalopram. 
Pittsburgh participants allocated to an initial treatment strategy of IPT were seen by 
masters- or doctoral-level psychologists or social workers for weekly 50-minute sessions.  These 
therapists were trained by either G. Klerman, M. Weissman, B. Rounsaville and E. Chevron or 
one of two clinicians initially trained by that group.  Pisa participants allocated to IPT were 
psychiatrists trained to research-level IPT competence by a co-investigator.  At both sites, IPT 
sessions were digitally voice recorded and rated for IPT specificity.  After six weeks of 
treatment, those participants initially allocated to IPT who had attended at least five sessions of 
IPT and had not evidence a response began treatment augmentation with SSRI. 
Participants in either initial treatment condition who complained of sleep difficulties were 
permitted up to two mg/day of lorazepam until the sleep difficulties resolved.  Similarly, any 
participant reporting agitation could receive up to four mg/day of lorazepam.  In practice, the 
median dose of lorazepam was 1.0 mg (range 0.25-3 mg)2
3.2.3 Assessment 
.  
Non-blind, independent clinical evaluators completed in-person intake psychiatric evaluations 
(SCID-I, -II), symptom assessments, and socio-demographic interviews, including medical 
                                                 
2 Lorazepam dose information is based on full study sample only (n = 303).  
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history, with potential participants.  Then, clinical evaluators reviewed each evaluation with a 
team of experts (i.e. the principal investigator, the project coordinator, and a study physician) to 
come to a consensus diagnosis for each potential participant.  Next, clinical evaluators and study 
investigators determined study eligibility based on inclusion and exclusion criteria.  Finally, 
eligible participants were randomized to an initial treatment strategy and informed of both their 
study eligibility and treatment condition.  The study coordinator contacted ineligible participants 
and provided an appropriate referral.    
To determine severity of depression and monitor treatment response, at each clinic visit, 
evaluators administered the HRSD-25 and participants completed the Quick Inventory of 
Depressive Symptoms, 16-Item (QIDS-16).  At entry to treatment (start of week one of 
treatment), evaluators administered the Interview on Suicidal Feelings (ISF) and participants 
completed various self-reports, including the Mood Spectrum - Lifetime (MOODS-Lifetime), the 
Panic-Agoraphobic Spectrum - Lifetime (PAS-Lifetime), and the Quality of Life and Satisfaction 
Questionnaire (Q-LES-Q).  After one week of treatment (start of week two of treatment), 
participants completed the Mood Spectrum – Past Month (MOODS-PM) and Panic-Agoraphobic 
Spectrum – Past Month (PAS-PM).  After six weeks of treatment (start of week seven of 
treatment), evaluators again administered the ISF and participants again completed the Q-LES-
Q.    
To ensure consistency between sites, a bilingual psychiatrist from Pisa was trained over 
the course of one year at Pittsburgh and certified as the "gold standard" rater for Pisa.  Inter-rater 
agreement at each site and between sites was recalibrated approximately every six months and 
was maintained at an intra-class coefficient (ICC) greater than 0.85. 
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3.2.3.1 Identification of MDD-SI 
We classified participants as experiencing an index episode that was either major depression 
without current, baseline suicidal ideation (MDD) or major depression with current, baseline 
suicidal ideation (MDD-SI).  Participants were classified as MDD-SI if they met at least one of 
the following criteria: 
 
(a) Endorsed a score of two (I think of suicide or death several times a week for several  
minutes) or three (I think of suicide or death several times a day in some detail, I have  
made specific plans for suicide, or I have actually tried to take my life) on QIDS  
Question 12: Thoughts of death or suicide, and/or 
 
(b) Received a score of two (Wishes to be dead or any thoughts of possible death to self)  
or three (Suicide ideas or gestures) on HRSD Question 3: Suicide, and/or  
 
(c) Answered, “Yes, within the past week,” to ISF Item 3: Thought to attempt, and/or  
 
(d) Answered, “Yes, within the past week,” to ISF Item 4: Seriously thought to attempt or  
made plans.   
 
First, this operational definition ensured that all participants with serious or continuous 
active suicidal ideation, with or without a plan, were classified as MDD-SI, regardless of 
whether they self-reported, expressed to the evaluator, or did both.  We believed that this 
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minimized the influence of potential assessment biases.  Second, these cut points categorized 
participants who experienced passive death ideation, (e.g. life is empty), as MDD.  We believe 
that death ideation is distinct from suicidal ideation.   
Notably, the HRSD Question 3 is incongruent with the definition of suicidal ideation in 
the Classification System of Self-directed Violence (CSSV) (Brenner et al., 2010); a score of two 
might indicate persistent death wishes without thoughts of engaging in suicidal behavior and a 
score of three might denote preparatory behaviors or gestures.  For the QIDS Question 12, a 
score of two is consistent with the CSSV definition of suicidal ideation but a score of three is 
inconsistent since it might include suicidal behaviors.  Similarly, ISF Item 3 is consistent, 
whereas ISF Item 4 is not because it might include preparatory behaviors. 
3.2.3.2 Identification of lifetime suicidality 
We identified participants as positive for a history of suicidal ideation, excluding index episode, 
if participants answered “Yes” to MOODS-Lifetime Questions 104 to 107.  These questions ask 
the participant whether he or she has ever experienced (either in isolation or as part of a 
depressive episode) periods of three to five days or more when he or she (104) wanted to die or 
hurt self, (105) made plans to die, (106) made an attempt to die, and (107) required medical 
attention after an attempt.  Questions 105, 106, and 107 are congruent with the CSSV. 
We categorized participants as positive for a history of suicide attempt if they answered 
“Yes” to (a) MOODS-Lifetime Question 106 and/or (b) MOODS-Lifetime Question 107 and/or 
(b) ISF Item 5: Attempted suicide.  Again, we believed that including both a self-report and 
interviewer rating of suicidality might minimize assessment bias.  
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3.2.3.3 Assessment measures 
The Hamilton Rating Scale for Depression (HRSD) (Hamilton, 1960) is an interviewer rating 
scale designed to assess the severity of depressive symptoms with a scale of zero to four or zero 
to two, where higher numbers indicate higher severity.  Researchers have used the HRSD as a 
principal outcome measure (Gibbons et al., 1993) and standard assessment of depression for 
more than 40 years (Bagby et al., 2004).  The HRSD-25 (Thase, Carpenter, Kupfer, & Frank, 
1991) is an adapted version of the original HRSD-17 and assesses reverse neurovegetative 
symptoms, including hypersomnia, oversleeping, napping, increased appetite, weight gain, 
psychic retardation, motor retardation, and diurnal variation.  After administering the HRSD-25 
interview, interviewers can parse the items, yielding an HRSD-17 score.  Moderate depression is 
indicated by a score between 15 or and 25.  Suicidal ideation is noted by a score of two (Wishes 
to be dead or any thoughts of possible death to self) or three (Suicide ideas or gestures) on 
Question 3.  Since our MDD-SI criteria included Question 3, to avoid inflating any potential 
statistical associations, we calculated adjusted HRSD scores by subtracting the zero to four score 
from the total HRSD-25 scores.  This adjusted score is specified as HRSD-25-A. 
The Quick Inventory of Depressive Symptomatology (QIDS) (Rush, Carmody, & Reimitz, 
2000; Trivedi et al., 2004) is a 16-item self-report questionnaire designed to measure the signs 
and symptoms of depression.  It has excellent psychometric properties (Rush et al., 2003).  Both 
somatic and cognitive features of depression, DSM-IV criteria, and subtypes of depression, such 
as atypical and melancholic features, are queried.  Most items are scored on a zero to three scale, 
where three indicates greatest severity.  All items are weighted equally in the composite score.  
Moderate depression is indicated by a score between 11 and 15.  Suicidal ideation is indicated by 
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a score of two (I think of suicide or death several times a week for several minutes) or three (I 
think of suicide or death several times a day in some detail, or I have made specific plans for 
suicide or have actually tried to take my life) on Question 12.  For the same reasons outlined for 
the HRSD-25-A scores, we calculated an adjusted score, the QIDS-A scores, by subtracting the 
zero to three score on the suicide item from the total QIDS scores.  
The Interview on Suicidal Feelings (ISF) (Paykel, Meyers, Lindenthal, & Tanner, 1974) 
is a 5-item structured interview composed of separate questions regarding suicide:  1) Have you 
ever had the feeling that life is not worth living?  2) Have you ever wished to die, for example, to 
go to sleep and not wake up again?  3) Have you ever thought of taking your own life, even 
though you would never do so?  4) Have you ever seriously considered taking your own life, or 
made plans on how to go about doing so?  5) Have you ever attempted to take your own life?  
Individuals that answer yes are asked if they experienced the symptom in the past week, two 
weeks to twelve months ago, or more than a year ago.  Psychometric properties are not 
established for this instrument.  
The Mood Spectrum Self-Report (MOODS) (Fagiolini et al., 1999) is a self-report 
instrument that evaluates the lifetime (MOODS-Lifetime) and past month (MOODS-PM) 
presence or absence of the full range of mood pathology someone may experience, including 
DSM-IV core symptoms of depression, hypomania and mania, atypical symptoms, subthreshold 
manifestations, and behavioral traits that arise as a means of coping with mood symptoms (See 
Section 2.6.).  The Spectrum Project Group has demonstrated that the MOODS has good internal 
consistency (0.79-0.92) and high test-retest reliability (r = 0.93-0.94) (Fagiolini et al., 1999; 
Rucci & Maser, 2000).  
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The Panic-Agoraphobic Spectrum Self-Report (PAS) (Cassano et al., 1999; Shear et al., 
2001) was designed to evaluate the lifetime (PAS-Lifetime) and past month (PAS-PM) presence 
or absence of a broad array of manifestations of panic disorder including DSM-IV core 
symptoms of panic, subthreshold manifestations, and behavioral traits that arise as a means of 
coping with anxiety symptoms (See Section 2.6.).  A total score that exceeds 35 is clinically 
significant.  The Spectrum Project Group has demonstrated that the PAS has high inter-rater 
reliability and test-retest reliability (r = 0.65-0.89), and strong concurrent validity (>0.65 
between PAS domains & instruments measuring similar constructs) (Rucci & Maser, 2000). 
The Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) (Endicott, Nee, 
Harrison, & Blumenthal, 1993; Rossi et al., 2005) is a self-report questionnaire designed to 
measure the degree of enjoyment and satisfaction an individual experiences in eight areas of life.  
These include physical health or activities, feelings, work, household duties, school or course 
work, leisure time activities, social relations, and general activities.  Items are scored on a one to 
five scale, where higher scores indicate higher levels of satisfaction.  The total score is the sum 
of the first fourteen items (raw score) minus fourteen (minimum possible score), divided by 56.  
The Q-LES-Q has substantive test–retest reliability and internal consistency (>0.80). 
3.3 DATA ANALYSIS 
For our investigation, we adopted the McArthur approach (Kraemer, Stice, Kazdin, Offord, & 
Kupfer, 2001; Kraemer, Wilson, Fairburn, & Agras, 2002) to conceptually distinguish among a 
non-specific predictor, moderator, and mediator variable.  Accordingly, there are four potential 
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relationships between suicidal ideation (SI) and initial treatment response (R).  One possibility is 
that SI is unrelated to R.  Another possibility is that SI moderates R.  If SI is a moderator, then SI 
is a pre-treatment/baseline characteristic, SI is uncorrelated with treatment (SSRI or IPT), and SI 
has an interactive effect (with or without a main effect) on R.  If our analyses demonstrate that SI 
is a moderator of R, then SI does not help explain the initial effect of treatment.  However, the 
interactive effect means that the effect of treatment on individual participants’ initial response 
depends on the presence of SI and thus, SI helps explain individual differences in the initial 
effect of treatment; presence of SI indicates on whom the treatment may have the most (or least) 
clinically significant initial effects.  A third possibility is that SI is a nonspecific predictor of R.  
If our analyses demonstrate that SI is a non-specific predictor of R, then SI is a pre-
treatment/baseline characteristic, SI is uncorrelated with treatment, and SI has a main effect but 
no interactive effect on R.  A fourth scenario is that SI mediates R.  However, a mediator is a 
variable or event that occurs during R, is correlated with R, and has a main or interactive effect 
with R.  Baseline SI does not meet these criteria.  Treatment-emergent SI or changes in baseline 
SI – neither of which we were examined in this investigation – may be mediators but cannot be 
moderators.  A moderator precedes and is not associated with that which it moderates; a mediator 
follows and is associated with that which it mediates. 
3.3.1 Assumption testing and preliminary analyses 
We conducted data analysis with SPSS Statistical Software, Version 17.0 (SPSS Inc., USA).  We 
examined the data for normality, multicollinearity and singularity, homoscedasticity, univariate 
and multivariate outliers, homogeneity of variance, and missing data.  Since our hypothesis 
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testing included a range of statistical techniques, and statistical techniques vary in robustness to 
modest violations of these assumptions, we tested assumptions for each hypothesis.  We 
manipulated the data when the statistical technique warranted.  Mainly, this included censoring 
outliers when Mahalanobis distances exceeded the critical value, or standardized residual or z-
score values were greater than +/- 3.3 (Tabachnick & Fidell, 2007).  Since the univariate 
analyses were only preliminary steps for evaluating the relationships among variables and 
suicidal ideation, we included all variables that were significant at p = 0.05, unless otherwise 
noted, in the logistic regression models.   
 To determine whether we should enter site as a covariate, we evaluated differences in ten 
socio-demographic variables and baseline clinical characteristics between sites with a one-way 
between-groups multivariate analysis of variance (MANOVA).  The dependent variables were: 
age, HRSD-25-A, Q-LES-Q score, ISF score, MOODS-Lifetime score, PAS-Lifetime score, 
MOODS-PM score, PAS-PM score, total number of past month anxiety diagnoses, and total 
number of lifetime anxiety diagnoses.  An overview of our analytical strategy is depicted in 
Figure 1.   
3.3.2 Hypothesis 1: Associated characteristics of MDD-SI 
To test Hypothesis 1, that individuals with MDD-SI and individuals with MDD will differ in pre-
treatment socio-demographic variables and baseline clinical characteristics, we first examined 
the relationships among socio-demographic variables and baseline clinical characteristics using 
Pearson product-moment correlation coefficients.  Then, we calculated Chi-square tests of 
independence with Yates Continuity Correction or Spearman’s rank correlation coefficients for  
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Figure 1. Overview of Analytical Strategy for Hypothesis Testing 
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categorical socio-demographic variables and baseline clinical characteristics.  Non-ranked 
categorical socio-demographic variables included: gender, marital status, employment status, and 
current smoking status.  Non-ranked categorical baseline clinical characteristics included: 
lifetime diagnosis of alcohol or substance abuse or dependence disorder, any anxiety disorder, 
generalized anxiety disorder, panic disorder with or without agoraphobia, agoraphobia, social 
phobia, specific phobia, obsessive compulsive disorder, post-traumatic stress disorder, and 
anxiety not otherwise specified.  Ranked categorical socio-demographic variables included: 
educational attainment, body mass index (BMI), and number of current medical conditions.  
Ranked categorical baseline clinical characteristics included: age of first MDE and number of 
previous MDEs (including current MDE).  Next, we conducted independent-samples t-tests for 
age and continuous baseline clinical characteristic, including HRSD-25-A score, QIDS-16-A 
score, and Q-LES-Q score.   
3.3.3 Hypothesis 2: Lifetime suicidality 
To test Hypothesis 2, that individuals with MDD-SI and individuals with MDD will differ in 
lifetime experience of suicidal ideation and history of suicide attempts, we calculated Chi-square 
tests of independence with Yates Continuity Correction.  To determine the relationships among 
self-report ratings (QIDS, MOODS-Lifetime, and MOODS-PM) and interviewer-ratings (HRSD, 
ISF) of suicidality, we calculated Pearson product-moment correlation coefficients. 
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3.3.4 Hypothesis 3: Phenomenology of MDD-SI 
To test Hypothesis 3, that individuals with MDD-SI and individuals with MDD will differ in 
lifetime and past month spectrum assessment total and factor scores, we first examined the 
relationships among the factor scores using Pearson product-moment correlation coefficients.  
Next, we conducted independent-samples t-tests for lifetime and past month MOODS total 
scores, MOODS adjusted scores (scores without suicide items), and PAS total scores.  Then, we 
used MANOVAs to test for differences between groups on the combined factor scores and, if 
statistically significant, to consider the factor scores separately.  Finally, with logistic regression, 
we assessed the impact of the factor scores that significantly distinguished the MDD and 
MDD_SI groups in the multivariate analyses, with and without pre-treatment socio-demographic 
variables and baseline clinical characteristics that significantly distinguished the MDD and 
MDD-SI groups in univariate analyses, on the likelihood that participants would report baseline 
suicidal ideation.   
3.3.5 Hypothesis 4: Initial treatment response 
To test Hypothesis 4, that current suicidal ideation is a non-specific predictor of initial treatment 
response, we conducted a two-way between-groups analysis of covariance (ANCOVA) to 
compare the efficacy of initial treatment strategy in reducing depression severity for individuals 
with MDD-SI and individuals with MDD.  The independent variables were initial treatment 
strategy (SSRI or IPT) and baseline group (MDD or MDD-SI).  We ran analyses with site and 
then site and baseline HRSD-25-A scores as covariates.  The dependent variable was HRSD-25-
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A scores after six weeks of treatment (Week 7 scores).  We considered the main effect for 
baseline group, the main effect for initial treatment strategy, and the interaction between baseline 
group and initial treatment strategy. 
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4.0  RESULTS 
4.1 SAMPLE CHARACTERISTICS 
A total of 368 outpatients with non-psychotic unipolar depression enrolled in the study; 182 
participants were randomly allocated to an initial treatment strategy of SSRI and 186 participants 
were randomly allocated to an initial treatment strategy of IPT.  Baseline data was analyzed for 
the entire sample.  As detailed in Figure 1, complete data was unavailable for 23 participants.   
Participants had a mean age of 39.44 years (SD = 12.17).  Participants mostly were 
female (71.74%), Caucasian (91.03%), not married (61.14%), and employed at least part-time 
(64.67%).  The majority had at least some college or advanced training (78.53%), BMI either in 
the normal range (43.75%) or overweight to severely obese range (48.37%), and either no 
medical conditions (46.74%) or one to two medical conditions (34.78%). 
Using study criteria, 85 (23.10%) participants were classified as experiencing MDD-SI 
and 283 (76.90%) participants were classified as experiencing MDD.  Means, standard 
deviations, and percentages within each group for lifetime and current suicidality at baseline are 
presented in Table 1. 
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Figure 2. CONSORT 2010 Flow Diagram for Pilot and Full Study 
 
 
Assessed for eligibility 
(n= 552) 
Excluded  (n= 153) 
-  Not meeting inclusion criteria (n=101) 
-  Declined to participate (n=39) 
-  Needed higher level of care (n=5) 
-  Other reasons (n= 8) 
 
 
Analyzed  (n= 186) 
 
-  Excluded from some analyses (n=13) 
Allocated to IPT (n=199) 
 
-  Received allocated intervention (n=186) 
-  Did not receive allocated intervention (n=13) 
Allocated to SSRI (n=200) 
 
-  Received allocated intervention (n=182) 
-  Did not receive allocated intervention (n=18) 
Analyzed  (n=182) 
 
-  Excluded from some analyses (n=10) 
 
Analysis 
Six Weeks of 
Treatment 
Randomized  
(n= 399) 
Enrollment 
Allocation 
56 
 
Table 1.  Lifetime and Current Suicidality at Intake to Treatment 
 
Assessment Item Group Total N X2 p 
 MDD 
N = 283 
MDD-SI 
N = 85 
 
368 
  
 N % N %    
History of suicidal ideationa 91 23.4 67 78.8 158 56.00 .00 
History of suicide attemptb 20 7.1 25 29.4 45 28.36 .00 
 
HRSD Suicide 
   0 Absent 
   1 Doubtful or trivial 
   2 Mild 
   3 Moderate 
   4 Severe, attempted 
 
195 
88 
0 
0 
0 
 
68.9 
31.1 
0 
0 
0 
 
15 
33 
37 
0 
0 
 
17.6 
38.8 
43.5 
0 
0 
 
210 
121 
37 
0 
0 
 
 
- 
 
 
QIDS Thoughts of death or suicide 
   0 Absent 
   1 Life is empty 
   2 Several times a week 
   3 Several times a day 
 
 
196 
83 
0 
0 
 
69.3 
29.3 
0 
0 
 
6 
49 
25 
3 
 
7.1 
57.6 
29.4 
3.5 
 
202 
132 
25 
3 
 
- 
 
 
ISF Thought to attempt 
   Past week 
   Two weeks to 12 months ago 
   More than a year ago 
 
105 
0 
56 
46 
37.1 
0 
19.8 
16.3 
70 
34 
29 
7 
82.4 
40.0 
34.1 
8.2 
175 
34 
85 
53 
- 
 
 
ISF Seriously thought to attempt 
   Past week 
   Two weeks to 12 months ago 
   More than a year ago 
 
30 
0 
8 
22 
10.8 
0 
2.8 
7.8 
39 
4 
16 
19 
45.9 
4.7 
18.8 
22.4 
69 
4 
24 
41 
-  
ISF Attempted suicide 
   Past week 
   Two weeks to 12 months ago 
   More than a year ago 
 
18 
0 
3 
15 
6.4 
0 
1.1 
5.3 
21 
0 
0 
21 
24.7 
0 
0 
24.7 
39 
0 
3 
36 
-  
ISF Total score 1.50 +1.44 3.31 +1.28 364 
 
  
Notes.  aDoes not include baseline ideation; b Data obtained from Lifetime Mood Spectrum and 
Interview of Suicidal Feelings (ISF); (-) Analysis not completed; HRSD = Hamilton Rating 
Scale for Depression; QIDS = Quick Inventory of Depressive Symptoms 
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4.2 TREATMENT SITE  
A one-way between-groups MANOVA indicated that there was a statistically significant 
difference between the Pittsburgh and Pisa samples on the combined dependent variables, F(10, 
323) = 28.74, p = .00; Pillai’s trace = .47; partial eta squared = .47.  When the results for the 
dependent variables were considered separately, using a Bonferroni adjusted alpha level of .005, 
five variables reached statistical significance: Q-LES-Q score F(1, 332) = 44.59, p = .000; ISF 
score, F(1, 332) = 8.24, p = .003; MOODS-Lifetime score, F(1, 332) = 9.18, p = .003; PAS-
Lifetime score, F(1, 332) = 40.37, p = .000; and PAS-PM score, F(1, 332) = 113.20, p = .000.  
Compared to the Pisa sample, the Pittsburgh sample had higher scores on the Q-LES-Q, ISF, and 
MOODS-Lifetime, and lower scores on the PAS-Lifetime and PAS-PM. Based on these 
differences, all hypothesis testing was conducted with site as a covariate. 
   
4.3 HYPOTHESIS 1: ASSOCIATED CHARACTERISTICS OF MDD-SI 
The strength of the relationships among socio-demographic variables and baseline clinical 
characteristics are presented in Table 2 and Table 3, respectively.  There were strong, positive 
correlations between age and marital status (r = .56) and HRSD-25-A and QIDS-16-A (r = .56). 
As shown in Table 4 and Table 5, chi-square tests of independence and independent-samples t-
tests indicated few differences in pre-treatment socio-demographic and baseline clinical 
characteristics between the MDD and MDD-SI groups.  The MDD-SI group included 
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significantly more participants from Pittsburgh than from Pisa, 63.5% versus 36.5%, 
respectively.  In the Pittsburgh sample (data was not available for the Pisa sample), the MDD-SI 
group was significantly more likely than was the MDD group to smoke, 16.5% versus 9.2%, 
respectively.  This difference remained significant after controlling for site differences (e.g., Q-
LES-Q, MOODS-Lifetime, PAS-Lifetime, and PAS-PM scores)  The MDD-SI group had 
significantly greater baseline depression severity, as indicated by higher HRSD-25-A scores (M 
= 25.85, SD = 5.53 versus M = 23.53, SD = 4.54) and QIDS-16-A scores (M = 15.24, SD = 4.15 
versus M = 11.99, SD = 4.09), and lower baseline life satisfaction and enjoyment, as indicated 
by lower Q-LES-Q scores (M = 33.59, SD = 8.18 versus M = 37.04, SD = 0.49).  These group 
differences remained significant when site was entered as a covariate.  As detailed in Table 6, 
there were no significant differences in the lifetime diagnosis of alcohol use, substance use, or 
anxiety disorders.  
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Table 2.  Correlations among Socio-Demographic Variables 
 
 
Variable 1 2 3 4 5 
1 Gender 
 
1.00 .09 -.15 
* 
.11 -.04 
2 Age 
 
 1.00 -.11 
** 
.12 .16 
* 
3 Educational attainment 
 
 1.00 -.06 .08 
4 Smoker status 
 
   1.00 -.09 
5 Body mass index 
 
   1.00 
Notes.  * Significant at 0.01 level (two-tailed); ** Significant at 0.05 level (two-
tailed); Male = 0, female = 1; Non-smoker = 0, smoker = 1 
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Table 3.  Correlations among Baseline Clinical Characteristics 
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Table 4.  Socio-Demographic Characteristics 
 
 
Variable Group Total 
N 
Stata p 
 MDD 
N = 283 
MDD-SI 
N = 85 
 
368 
  
 N % N %    
Study site 
   Pittsburgh, USA 
   Pisa, Italy 
 
 
142 
141 
 
 
50.2 
49.8 
 
 
54 
31 
 
 
63.5 
36.5 
 
196 
172 
4.16 .04 
Gender 
   Male 
   Female 
 
 
74 
209 
 
26.1 
73.9 
 
30 
55 
 
35.3 
64.7 
 
104 
264 
2.27 n.s. 
Age 39.67 
 
+ 12.33 38.68 + 11.70 368 t = 
0.66 
 
n.s. 
Race and ethnicity  
   Caucasian 
   African-American 
   Asian 
   Other or declined 
 
 
257 
17 
3 
6 
 
90.8 
6.0 
1.1 
2.1 
 
78 
1 
2 
4 
 
91.8 
1.2 
2.4 
4.7 
 
335 
18 
5 
10 
 
- 
 
 
Marital status 
   Never married 
   Married or living with 
partner 
   Separated or divorced 
   Widowed 
 
 
117 
115 
38 
13 
 
41.3 
40.6 
13.4 
4.6 
 
40 
28 
16 
1 
 
47.1 
32.9 
18.8 
1.2 
 
157 
143 
54 
14 
4.80 n.s. 
Educational attainment 
   Less than HS diploma 
   HS diploma or GED 
   Some college or adv. train. 
   College degree 
   Advanced degree 
 
 
48 
14 
127 
30 
64 
 
17.0 
4.9 
44.9 
10.6 
22.6 
 
9 
8 
37 
14 
17 
 
10.6 
9.4 
43.5 
16.5 
20.0 
 
57 
22 
164 
44 
81 
ρ = 
0.03 
n.s. 
Notes.  aX2 test statistic presented unless otherwise noted; (-) = Analysis was not 
conducted.   
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Table 4.  Socio-Demographic Characteristics (con’t) 
 
 
 
 
Variable Group Total 
N 
Stat a p 
 MDD 
N = 283 
MDD-SI 
N = 85 
 
368 
  
 N % N %    
Employment status 
   Full-time 
   Part-time 
   Homemaker or retired 
   Student 
   Unemployed, laid off,   
      disabled, on leave, or other 
 
 
157 
35 
30 
26 
 
34 
 
55.7 
12.4 
10.6 
9.2 
 
12.1 
 
38 
8 
9 
13 
 
17 
 
44.7 
9.4 
10.6 
15.3 
 
20.0 
 
195 
43 
39 
39 
 
51 
7.21 n.s. 
Smoking status (Pittsburgh, only) 
   Current smoker 
    
 
26 
 
9.2 
 
14 
 
16.5 
 
53 
3.96 .05 
Body mass index (BMI) 
   Under-weight, < 18.5 
   Normal, 18.5 – 24.9 
   Overweight, 25.0 – 29.9 
   Obese, 30.0 – 34.9 
   Severely obese, > 35.0 
 
 
12 
120 
83 
29 
27 
 
4.4 
44.3 
30.6 
10.7 
10.0 
 
3 
41 
18 
10 
11 
 
3.6 
49.4 
21.7 
12.0 
13.3 
 
15 
161 
101 
39 
38 
ρ = 
-0.01 
n.s. 
Number of current medical 
conditions 
   No conditions 
   1 or 2 conditions 
   3 or more conditions 
 
 
 
127 
102 
26 
 
 
49.8 
40.0 
10.2 
 
 
45 
26 
9 
 
 
56.3 
32.5 
11.3 
 
 
172 
128 
35 
ρ = 
-0.04 
 
n.s. 
Notes.  aX2 test statistic presented unless otherwise noted; (-) = Analysis was not conducted. 
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Table 5.  Baseline Clinical Characteristics 
 
 
 
Variable Group 
 
Total 
N 
Stata p 
 MDD 
N = 283 
MDD-SI 
N = 85 
 
368 
  
 M 
N 
SD 
% 
M 
N 
SD 
% 
   
HRSD-25 score 
 
23.84 
 
+ 4.57 
 
27.27 + 5.80 368 -  
        
HRSD-25-A scoreb 
 
23.53 
 
+ 4.54 25.85 5.53 367 t =  
-3.50 
 
.00 
        
QIDS-16 score 
 
12.29 
 
+ 4.24 16.54 + 4.46 362 -  
        
QIDS-16-A scoreb 
 
11.99 + 4.09 15.24 + 4.15 362 t =  
-6.34 
 
.00 
        
Q-LES-Q score 
 
37.04 + 0.49 33.59 + 8.18 352 t = 
3.52 
 
 
.00 
Age of first MDE 
   Before age 12 
   Between age 13 and age 18 
   After age 18 
 
 
18 
50 
209 
 
6.5 
18.1 
75.5 
 
11 
21 
53 
 
12.9 
24.7 
62.4 
 
29 
71 
266 
ρ = 
-0.08 
n.s. 
Number of MDEs 
   1 MDE 
   2 to 3 MDEs 
   4 to 5 MDEs  
   6 or more MDEs 
    
 
91 
99 
41 
49 
 
32.5 
35.4 
14.6 
17.5 
 
24 
30 
12 
18 
 
28.6 
35.7 
14.3 
21.4 
 
115 
129 
53 
67 
ρ = 
0.04 
n.s. 
Notes.  a X2 test statistic presented unless otherwise noted; b Adjusted score does not include 
suicide items; (-) = Analysis was not conducted.  HRSD-25 = Hamilton Rating Scale for 
Depression, 25-item; QIDS-16 = Quick Inventory of Depressive Symptoms, 16-item; Q-LES-Q = 
Quality of Life Enjoyment and Satisfaction Questionnaire; MDE = Major depressive episode  
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Table 6.  Alcohol, Substance, and Anxiety Comorbidity 
 
 
 
Variable Group Total 
N 
X2 p 
 MDD 
N = 283 
MDD-SI 
N = 85 
 
368 
  
 N % N %    
Alcohol abuse or 
dependence 
       
   Lifetime a 
 
23 8.1 12 14.1 35 2.07 n.s. 
Drug abuse or 
dependence 
       
   Lifetime 
 
18 6.4 8 9.4 26 0.52 n.s. 
Any comorbid anxiety 
disorders  
       
   Past month 125 44.2 42 50.0 167 0.69 n.s. 
   Lifetime 
 
139 49.1 47 55.3 186 0.77 n.s. 
Generalized anxiety        
   Past month 55 19.4 22 25.9 77 1.23 n.s. 
   Lifetime 
 
58 20.5 22 25.9 80 0.82 n.s. 
Panic with or without 
agoraphobia 
       
   Past month 38 13.4 11 12.9 49 0.00 n.s. 
   Lifetime 
 
57 20.1 15 17.6 72 0.12 n.s. 
Agoraphobia        
   Past month 14 4.9 7 8.2 21 0.77 n.s. 
   Lifetime 
 
19 6.7 8 9.4 27 0.36 n.s. 
Social phobia        
   Past month 19 6.7 12 14.1 31 3.74 n.s. 
   Lifetime 
 
21 7.4 12 14.1 33 2.82 n.s. 
Note.  a Lifetime totals include past month cases.  
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Table 6.  Alcohol, Substance, and Anxiety Comorbidity (con’t) 
 
 
4.4 HYPOTHESIS 2: LIFETIME SUICIDALITY 
As detailed in Table 1, chi-square tests of independence demonstrated statistically significant 
differences between the MDD and MDD-SI groups for lifetime experience of suicidal ideation 
and history of suicide attempts.  The MDD-SI group was significantly more likely than was the 
MDD group to report a lifetime experience of suicidal ideation (80.7% versus 23.4%, 
 
Variable Group Total 
N 
X2 p 
 MDD 
N = 283 
MDD-SI 
N = 85 
 
368 
  
 N % N %    
Specific phobia        
   Past month 17 6.0 4 4.7 21 0.04 n.s. 
   Lifetime 
 
18 6.4 5 5.9 23 0.00 n.s. 
Obsessive compulsive        
   Past month 7 2.5 4 4.7 11 1.28 n.s. 
   Lifetime 
 
9 3.2 4 4.7 13 0.11 n.s. 
Post-traumatic stress        
   Past month 5 1.8 5 5.9 10 2.78 n.s. 
   Lifetime 
 
8 2.8 5 5.9 13 1.01 n.s. 
Anxiety not otherwise 
specified 
       
   Past month 4 1.4 2 2.4 6 0.01 n.s. 
   Lifetime 
 
4 1.4 2 2.4 6 0.01 n.s. 
Note.  a Lifetime totals include past month cases.  
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respectively) and history of suicide attempts (29.4% versus 7.1%, respectively).  When site was 
entered as a covariate, the relationship between group and suicidal ideation remained significant.  
There was insufficient power to test for site effects on history of suicide attempts.  
The correlations among self-report (QIDS, MOODS-Lifetime, and MOODS-PM) and 
interviewer ratings of suicidality (HRSD, ISF) are presented in Table 7.  There were strong, 
positive correlations between the HRSD and QIDS (r = .58), ISF Thought to attempt and 
MOODS-Lifetime Wanted to die, (r = .53), and MOODS-Lifetime Made plan to die and 
MOODS-Lifetime Required medical attention after attempt (r = .63).  There was a strong, 
negative correlation between the MOODS-Lifetime Wanted to die and MOODS-Lifetime Made 
plan to die, (r = -.54). 
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Table 7.  Correlations among Interviewer and Self-report Ratings of Suicidality 
 
 
 
 1 2 3 4 5 6 7 8 9 
1 HRSD Suicide 
 
1.0 .58 
** 
.31 
** 
.33 
** 
.20 
** 
.35 
** 
-.25 
** 
.14 
** 
-.04 
2 QIDS Thoughts of death or suicide 
 
1.0 .35 
** 
.27 
** 
.05 .44 
** 
-.34 
** 
.06 -.00 
3 ISF Thought to attempt 
 
  1.0 .46 
** 
.28 
** 
.53 
** 
-.39 
** 
.28 
** 
-.15 
** 
4 ISF Seriously thought to attempt 
 
  1.0 .63 
** 
.47 
** 
-.25 
** 
.55 
** 
-.24 
** 
5 ISF Made attempt 
 
    1.0 .34 
** 
-.20 
** 
.81 
** 
-.36 
** 
6 MOODS-L Wanted to die/hurt self 
                     
    1.0 -.54 
** 
.34 
** 
-.15 
** 
7 MOODS-L Made plan to die 
 
      1.0 -.17 
** 
.46 
** 
8 MOODS-L Made attempt 
 
       1.0 -.41 
** 
9 MOODS-L Required medical 
attention after attempt 
 
        1.0 
Notes.  HRSD = Hamilton Rating Scale for Depression; QIDS = Quick Inventory of Depressive 
Symptoms; ISF = Interview of Suicidal Feelings; MOODS-L = Lifetime Mood Spectrum  
* Significant at 0.01 level (two-tailed); ** Significant at 0.05 level (two-tailed)  
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4.5 HYPOTHESIS 3: PHENOMENOLOGY OF MDD-SI 
The strength of the relationships among MOODS-Lifetime, PAS-Lifetime, MOODS-PM, and 
PAS-PM factor scores are presented in Table 8, Table 9, Table 10, and Table 11, respectively.  
There were multiple moderate and strong correlations. 
As shown in Table 12, independent-samples t-tests indicated significant differences 
between the MDD and MDD-SI groups for lifetime and past month MOODS total scores,, such 
that the MDD-SI group had significantly higher scores. 
One-way between-groups MANOVAs were performed to investigate differences between 
groups on the lifetime and past month MOODS and PAS factor scores.  Site was entered as a 
covariate in each MANOVA.  As reported in Table 13 and Table 14, there were statistically 
significant differences between the groups on the combined MOODS-Lifetime factor scores, 
F(14, 355) = 8.29, p = .00; PAS-Lifetime factor scores, F(10, 362) = 1.91, p = .04; MOODS-PM 
factor scores, F(14, 356) = 9.54, p = .00; and PAS-PM factor scores, F(10, 356) = 1.72, p = .05.  
When the results for the dependent variables were considered separately, eleven factors reached 
statistical significance: MOODS-Lifetime: depressive mood, psychomotor retardation, psychotic 
features, and euphoria; PAS-Lifetime: depersonalization; MOODS-PM: depressive mood, 
psychomotor retardation, and psychotic features; and PAS-PM: separation anxiety, agoraphobia, 
and depersonalization. 
Four logistic regression analyses were performed to determine the impact of the eleven 
spectrum factors on the likelihood that participants would report baseline suicidal ideation.  The 
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first model, shown in Table 15 (Model 1), included only site and lifetime spectrum factor scores.  
As a whole, Model 1 explained between 6.8% (Cox and Snell R square) and 10.3% (Nagelkerke 
R squared) of the variance in baseline ideation status.  The sensitivity of the model (true 
positives) was 2.4%; the specificity (true negatives) was 98.2%.  Overall, Model 1 correctly 
classified 76.2% of cases.  None of the variables made a unique statistically significant 
contribution to the model.  
The second model, presented in Table 16 (Model 2), included site, significant socio-
demographic variables and baseline clinical characteristics, and lifetime spectrum factor scores.  
This model was an improvement over the first model; it explained between 22.5% (Cox and 
Snell R square) and 34.6% (Nagelkerke R squared) of the variance in baseline ideation status.  
The sensitivity of the model was 38.2%; the specificity was 93.7%.  Correct classification was 
81.4%.  Four of the variables made statistically significant and unique contributions to Model 2: 
site, Q-LES-Q score, lifetime experience of suicidal ideation, and MOODS-Lifetime euphoria. 
The third model, reported in Table 17 (Model 3), included only site and past month 
spectrum factor scores.  This model explained between 9.4% (Cox and Snell R square) and 
14.2% (Nagelkerke R squared) of the variance in baseline ideation status.  The sensitivity of the 
model was 4.8%; the specificity was 98.9%.  Correct classification was 76.7%.  Only MOODS-
PM depressive mood made a statistically significant and unique contribution to Model 3. 
The fourth model, detailed in Table 18 (Model 4), included site, significant socio-
demographic variables and baseline clinical characteristics, and past month spectrum factor 
scores.  As a whole, the model explained between 23.7% (Cox and Snell R square) and 36.2% 
(Nagelkerke R squared) of the variance in baseline ideation status.  The sensitivity of the model 
was 47.4%; the specificity was 93.5%.  The model correctly classified 83.1% of cases.  Only site 
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and lifetime experience of suicidal ideation made statistically significant and unique 
contributions to Model 4.  This was the best fitting model. 
 
4.6 HYPOTHESIS 4: INITIAL TREATMENT RESPONSE 
Controlling for site, an ANCOVA indicated a significant main effect for baseline group, F(1, 
340)=14.77, p =. 000, no main effect for initial treatment strategy, F(1, 340)=0.11, p =.744, and 
no group-treatment interaction effect, F(1, 340)=0.06, p =.810.  The effect size for baseline 
group was small; baseline group explained 4.2% of the variance in HRS-D-25-A scores after six 
weeks of treatment. 
Controlling for site and baseline depression severity, an ANCOVA indicated a significant 
main effect for baseline group, F(1, 338)=6.10, p =.014, no main effect for initial treatment 
strategy, F(1, 338)=0.31, p =.580, and no group-treatment interaction effect, F(1, 338)=0.88, p 
=.349.  The effect size for baseline group was small; baseline group explained 1.8% of the 
variance in HRS-D-25-A scores after six weeks of treatment. 
As detailed in Table 19, after six weeks of treatment, the MDD-SI group continued to 
have significantly higher scores compared to the MDD group on assessments of suicidality and 
depression severity.  Means and standard deviations for baseline group (MDD or MDD-SI) by 
initial treatment strategy (SSRI or IPT) are presented in Table 20.   
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Table 8.  Correlations among Lifetime Mood Spectrum Factors 
 
 
 
 1 2 3 4 5 6 7 8 9 10 11 12 13   
1 Depressive mood 
 
1.0 .62 
** 
.41 
** 
.35 
** 
.37 
** 
.49 
** 
.25 
** 
.31 
** 
.21 
** 
.10 .09 .34 
** 
.26 
** 
 
 
 
 
2 Psych. retardation 
 
 1.0 .39 
** 
.25 
** 
.44 
** 
.50 
** 
.38 
** 
.31 
** 
.29 
** 
.13 
* 
.22 .41 .29 
** 
 
 
 
 
3 Suicidality 
 
  1.0 .12 
* 
.29 
** 
.24 
** 
.17 
** 
.13 
* 
.11 
* 
.01 .06 .21 
** 
.08  
 
 
 
4 Drug or illness related depression 
 
 1.0 .13* .30 
** 
.12 
* 
.40 
** 
.14 
** 
.19 
** 
.07 .33 
** 
.19 
** 
 
 
 
 
5 Psychotic features 
 
    1.0 .28 
** 
.47 
** 
.25 
** 
.27 
** 
.09 .26 
** 
.44 
** 
.41 
** 
 
 
 
 
6 Neurovegetative  
 
     1.0 .29 
** 
.32 
** 
.23 
** 
.14 
** 
.10 .36 .19 
** 
 
 
 
 
7 Psych. activation 
 
      1.0 .30 
** 
.53 
** 
.44 
** 
.40 
** 
.45 
** 
.54 
** 
 
 
 
 
8 Creativity 
 
       1.0 .38 
** 
.40 
** 
.21 
** 
.36 
** 
.34 
** 
 
 
 
 
9 Mixed instability 
 
        1.0 .52 
** 
.34 
** 
.34 
** 
.44 
** 
 
 
 
 
10 Sociability and extroversion         1.0 .24 
** 
.28 
** 
.36 
** 
 
 
 
 
11 Spirituality 
 
          1.0 .30 
** 
.39 
** 
 
 
 
 
12 Mixed irritability 
 
           1.0 .43 
** 
 
 
 
 
13 Inflated self-esteem 
 
            1.0  
 
 
 
14 Euphoria 
 
               
 
15 Recklessness                
Notes.   Psych = psychomotor;  * Significant at 0.01 level (two-tailed); ** Significant at 0.05 level (two-tailed)  
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Table 9.  Correlations among Lifetime Panic-Agoraphobic Spectrum Factors 
 
 1 2 3 4 5 6 7 8 9 10 
1 Panic symptoms 
 
1.0 .58 .65 .36 .30 .70 .40 .61 .66 .26 
2 Separation anxiety 
 
 1.0 .61 .33 .41 .50 .42 .54 .58 .41 
3 Agoraphobia 
 
  1.0 .33 .33 .60 .32 .62 .70 .28 
4 Medical reassurance 
 
   1.0 .27 .30 .23 .48 .43 .20 
5 Rescue object 
 
    1.0 .24 .27 .33 .34 .27 
6 Depersonalization 
 
     1.0 .30 .55 .53 .27 
7 Family reassurance 
 
      1.0 .33 .30 .21 
8 Drug phobia 
 
       1.0 .54 .28 
9 Claustrophobia 
 
        1.0 .22 
10 Loss sensitivity 
 
         1.0 
Note.   All correlations are significant at the 0.01 level (two-tailed). 
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Table 10.  Correlations among Past Month Mood Spectrum Factors 
 
 
 
 
 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
1 Depressive mood 
 
1.0 .74 
** 
.43 
** 
.32 
** 
.54 
** 
.57 
** 
.30 
** 
.07 .15 
** 
-.03 .11 
* 
.49 
** 
.16 
** 
.04 .21 
** 
2 Psych. retardation 
 
 1.0 .37 
** 
.29 
** 
.51 
** 
.55 
** 
.37 
** 
.10 .14 
** 
.00 .12 
* 
.51 
** 
.18 
** 
.05 .20 
** 
3 Suicidality 
 
  1.0 .17 
** 
.28 
** 
.26 
** 
.16 
** 
.05 .10 .01 .11 
* 
.20 
** 
.09 -.02 .18 
** 
4 Drug or illness related depression 
 
 1.0 .24 
** 
.21 
** 
.14 
** 
.08 .24 
** 
.01 -.01 .32 
** 
.13 
* 
.02 .08 
5 Psychotic features     1.0 .34 
** 
.46 
** 
.19 
** 
.23 
** 
.06 .27 
** 
.50 
** 
.35 
** 
.12 
* 
-.24 
** 
6 Neurovegetative  
 
     1.0 .22 
** 
.11 
* 
.10 .04 .08 .38 
** 
.14 
* 
-.05 .23 
** 
7 Psych. activation 
 
      1.0 .33 
** 
.34 
** 
.25 
** 
.23 
** 
.54 
** 
.45 
** 
.26 
** 
.24 
** 
8 Creativity 
 
       1.0 .30 
** 
.48 
** 
.30 
** 
.23 
** 
.32 
** 
.40 
** 
.20 
** 
9 Mixed instability 
 
        1.0 .27 
** 
.26 
** 
.20 
** 
.23 
** 
.24 
** 
.30 
** 
10 Sociability and extroversion 
 
       1.0 .12 
* 
.18 
** 
.22 
** 
.51 
** 
.19 
** 
11 Spirituality 
 
          1.0 .21*
* 
.23 
** 
.12 
* 
.22 
** 
12 Mixed irritability 
 
           1.0 .33 
** 
.19 
** 
.27 
13 Inflated self-esteem 
 
            1.0 .26 
** 
.19 
** 
14 Euphoria 
 
             1.0 .17 
** 
15 Recklessness               1.0 
Notes.   Psych = psychomotor * Significant at 0.01 level (two-tailed); ** Significant at 0.05 level (two-tailed)  
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Table 11.  Correlations among Past Month Panic-Agoraphobic Spectrum Factors 
 
 
 
 
 1 2 3 4 5 6 7 8 9 10 
1 Panic symptoms 
 
1.0 .58 .66 .28 .36 .71 .48 .60 .59 .34 
2 Separation anxiety 
 
 1.0 .60 .32 .29 .51 .44 .50 .50 .34 
3 Agoraphobia 
 
  1.0 .27 .43 .61 .36 .60 .65 .29 
4 Medical reassurance 
 
   1.0 .26 .26 .26 .39 .26 .08 
5 Rescue object 
 
    1.0 .33 .21 .39 .39 .25 
6 Depersonalization 
 
     1.0 .38 .58 .49 .32 
7 Family reassurance 
 
      1.0 .40 .37 .27 
8 Drug phobia 
 
       1.0 .50 .18 
9 Claustrophobia 
 
        1.0 .28 
10 Loss sensitivity 
 
         1.0 
Note.   All correlations are significant at the 0.01 level (two-tailed). 
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Table 12.  Mood and Panic-Agoraphobic Spectrum Total Scores 
 
Score Group t p 
 MDD 
N = 283 
MDD-SI 
N = 85 
  
 M SD M SD   
MOODS Lifetime 
 
63.71 23.39 74.29 20.91 -3.75 .00 
MOODS Lifetime-Adjusteda 
 
64.42 22.80 71.07 20.44 -3.14 .00 
PAS Lifetime 
 
31.14 18.94 33.54 22.44 -0.89 n.s. 
MOODS Past Month  
 
40.63 19.49 52.12 18.44 -4.79 .00 
MOODS Past Month-
Adjusteda  
 
40.04 19.15 49.94 17.68 -4.21 .00 
PAS Past Month 
 
16.50 15.11 18.31 16.64 -0.93 n.s. 
Notes.  aScore does not include suicide items 
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Table 13.  Lifetime Spectrum Factor Scores 
 
 
 
 
Variable Group Fa p 
 MDD 
N = 283 
MDD-SI 
N = 85 
 
 
 
 M SD M SD   
Depressive mood 
 
14.46 6.05 17.24 4.11 11.64 .00 
Psychomotor retardation 
 
8.05 4.30 9.84 3.57 9.41 .00 
Drug or illness  
related depression 
 
0.78 1.11 0.96 1.18 0.68 n.s. 
Psychotic features 
 
2.65 1.49 2.94 1.40 3.75 .05 
Neurovegetative symptoms 
 
6.13 2.58 6.40 2.71 0.02 n.s. 
Psychomotor activation 
 
4.94 3.23 5.41 3.38 2.28 n.s. 
Creativity 
 
1.51 1.50 1.86 1.83 1.71 n.s. 
Mixed instability 
 
4.07 3.01 4.39 2.86 0.37 n.s. 
Sociability and extroversion 
 
2.11 1.86 2.39 1.99 1.37 n.s. 
Spirituality 
 
0.55 0.95 0.73 1.20 2.26 n.s. 
Mixed irritability 
 
2.48 1.59 2.78 1.64 2.00 n.s. 
Inflated self-esteem 
 
1.39 1.51 1.58 1.52 0.87 n.s. 
Euphoria 
 
2.04 1.64 2.53 1.80 6.26 .01 
Recklessness 1.53 1.32 1.62 1.28 0.00 n.s. 
 
Notes.  aA one-way between-groups multivariate analysis of variance with site as a 
covariate indicated a statistically significant difference between groups on the combined 
Mood Spectrum Lifetime factor scores 
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Table 13. Lifetime Spectrum Factor Scores (con’t) 
 
  
 
Variable Group Fa p 
 MDD 
N = 283 
MDD-SI 
N = 85 
  
 M SD M SD   
Panic symptoms 
 
7.72 4.81 7.93 4.98 0.98 n.s. 
Separation anxiety 
 
3.45 2.70 3.71 3.30 2.22 n.s. 
Agoraphobia 
 
4.24 3.96 4.59 4.46 1.06 n.s. 
Medical reassurance 
 
0.85 1.24 0.74 1.22 0.01 n.s. 
Rescue object 
 
0.59 0.93 0.50 0.82 0.03 n.s. 
Depersonalization 
 
3.51 2.89 4.50 2.90 10.49 .00 
Family reassurance 
 
1.57 1.21 1.49 1.17 0.06 n.s. 
Drug phobia 
 
2.95 2.66 2.71 2.73 0.06 n.s. 
Claustrophobia 
 
2.37 2.35 2.43 2.69 0.77 n.s. 
Loss sensitivity 
 
1.45 1.07 1.67 1.06 2.44 n.s. 
Notes.  aA one-way between-groups multivariate analysis of variance with site as a 
covariate indicated a statistically significant difference between groups on the combined 
Panic-Agoraphobic Lifetime factor scores  
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Table 14.  Past Month Spectrum Factor Scores 
 
 
 
 
Variable Group Stata p 
 MDD 
N = 283 
MDD-SI 
N = 85 
 
 
 
 M SD M SD   
Depressive mood 
 
12.18 6.04 15.99 5.14 27.30 .00 
Psychomotor retardation 
 
6.56 4.31 9.07 3.95 22.70 .00 
Drug or illness related 
depression 
 
0.46 0.82 0.60 0.85 1.64 n.s 
Psychotic features 
 
1.87 1.43 2.35 1.44 7.00 .00 
Neurovegetative symptoms 
 
4.20 2.39 4.77 2.32 3.33 n.s. 
Psychomotor activation 
 
2.35 2.29 2.58 2.41 0.63 n.s. 
Creativity 
 
1.02 1.65 0.90 1.55 0.33 n.s. 
Mixed instability 
 
0.32 0.71 0.44 0.87 1.67 n.s. 
Sociability and extroversion 
 
0.65 1.05 0.65 1.11 0.00 n.s. 
Spirituality 
 
0.14 0.54 0.24 0.69 2.02 n.s. 
Mixed irritability 
 
1.78 1.48 2.02 1.33 1.89 n.s. 
Inflated self-esteem 
 
0.62 1.01 0.73 1.03 0.74 n.s. 
Euphoria 
 
0.69 1.15 0.71 1.14 0.04 n.s. 
Recklessness 0.55 0.82 0.75 0.98 3.56 n.s. 
Notes.  aA one-way between-groups multivariate analysis of variance with site as a covariate 
indicated a statistically significant difference between groups on the combined Mood 
Spectrum Past Month factor scores 
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Table 14.  Past Month Spectrum Factor Scores (con’t) 
 
 
 
 
 
Variable Group Stata p 
 MDD 
N = 283 
MDD-SI 
N = 85 
  
 M SD M SD   
Panic symptoms 
 
4.42 4.22 4.85 4.62 0.63 n.s. 
Separation anxiety 
 
1.68 2.24 2.01 2.66 1.29 .02 
Agoraphobia 
 
2.14 2.93 2.60 3.57 1.40 .05 
Medical reassurance 
 
0.33 0.85 0.26 0.73 0.50 n.s. 
Rescue object 
 
0.36 0.73 0.44 0.73 0.71 n.s. 
Depersonalization 
 
2.03 2.40 2.79 2.88 5.77 .00 
Family reassurance 
 
1.17 1.19 1.11 1.17 0.20 n.s. 
Drug phobia 
 
1.66 2.22 1.60 2.27 0.05 n.s. 
Claustrophobia 
 
1.05 1.58 1.20 2.02 0.53 n.s. 
Loss sensitivity 
 
0.78 0.86 0.90 0.90 1.33 n.s. 
Notes.  aA one-way between-groups multivariate analysis of variance with site as a covariate 
indicated a statistically significant difference between groups on the combined Panic-
Agoraphobic Past Month factor scores 
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Table 15.  Model 1: Logistic Regression Predicting Baseline Suicidal Ideation from Lifetime 
Spectrum Factors 
 
 
Predictor B S.E. Wald X2 p Odds Ratio 
Site 
 
0.39 0.31 1.48 .211 0.80 2.73 
MOODS-Life 
   Depressive mood 
 
0.06 0.04 1.07 .071 1.00 1.14 
MOODS-Life 
   Psychomotor retardation 
 
0.03 0.04 1.03 .528 0.94 1.12 
MOODS-Life 
   Psychotic symptoms 
 
-0.07 0.11 0.94 .549 0.76 1.16 
MOODS-Life 
   Euphoria 
 
0.11 0.08 1.12 .141 0.96 1.30 
PAS-Life 
   Depersonalization 
 
0.10 0.05 1.10 .058 1.00 1.22 
Notes.  MOODS-Life = Mood Spectrum, Lifetime; PAS-Life = Panic-Agoraphobic 
Spectrum, Lifetime 
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Table 16.  Model 2: Logistic Regression Predicting Baseline Suicidal Ideation from Lifetime 
Spectrum Factors, Socio-Demographic Variables, and Baseline Clinical Characteristics 
 
 
 
 
Predictor B S.E. Wald X2 p Odds Ratio 
Site 
 
1.21 0.42 3.36 .00 1.46 7.71 
Baseline HRSD-25-A scorea 
 
0.04 0.03 1.05 .19 0.98 1.12 
Q-LES-Q score 
 
-0.07 0.02 0.93 .00 0.89 0.98 
Age of first MDE 
 
0.07 0.53 1.07 .90 0.38 3.02 
History of suicidal ideation 
 
-1.97 0.38 0.14 .00 0.07 0.29 
History of suicide attempt 
 
-0.75 0.43 0.47 .08 0.20 1.10 
MOODS-Life 
   Depressive mood 
 
 
0.02 
 
0.04 
 
1.02 
 
.63 
 
0.94 
 
1.11 
MOODS-Life 
   Psychomotor retardation 
 
-0.03 0.05 0.97 .54 0.87 1.07 
MOODS-Life 
   Psychotic symptoms 
 
-0.08 0.13 0.92 .53 0.71 1.19 
MOODS-Life 
   Euphoria 
 
0.19 0.09 1.21 .04 1.01 1.44 
PAS-Life 
   Depersonalization 
 
-0.03 0.07 0.97 .63 0.85 1.10 
Notes. aScore does not include suicide items; HRSD-25 = Hamilton Rating Scale for 
Depression, 25-item; QIDS-16 = Quick Inventory of Depressive Symptoms, 16-item; Q-
LES-Q = Quality of Life Enjoyment and Satisfaction Questionnaire; MDE = Major 
depressive episode; MOODS-Life = Mood Spectrum, Lifetime; PAS-Life = Panic-
Agoraphobic Spectrum, Lifetime 
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Table 17.  Model 3: Logistic Regression Predicting Baseline Suicidal Ideation from Past 
Month Spectrum Factors 
 
 
 
 
 
Predictor B S.E. Wald X2 p Odds Ratio 
Site 
 
0.63 0.33 1.88 .06 0.98 3.62 
MOODS-PM 
   Depressive mood 
 
0.09 0.04 1.09 .02 1.02 1.18 
MOODS-PM 
   Psychomotor retardation 
 
0.05 0.05 1.06 .26 0.96 1.16 
MOODS-PM 
   Psychotic symptoms 
 
0.01 0.12 1.01 .94 0.80 1.27 
PAS-PM 
   Separation anxiety 
 
0.06 0.08 1.06 .44 0.92 1.23 
PAS-PM 
   Agoraphobia 
 
-0.05 0.06 0.95 .36 0.85 1.06 
PAS-PM 
   Depersonalization 
 
0.06 0.07 1.06 .38 0.93 1.22 
Notes.  MOODS-PM = Mood Spectrum, Past Month; PAS-PM = Panic-Agoraphobic 
Spectrum, Past Month 
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Table 18.  Model 4: Logistic Regression Predicting Baseline Suicidal Ideation from Past 
Month Spectrum Factors, Socio-Demographic Variables, and Baseline Clinical 
Characteristics 
 
 
 
Predictor B S.E. Wald X2 P Odds Ratio 
Site 
 
1.20 0.43 3.00 .01 1.28 7.00 
Baseline HRSD-25-A scorea 
 
0.00 0.04 1.00 .97 0.94 1.07 
Q-LES-Q score 
 
-0.05 0.03 0.95 .04 0.90 1.00 
Age of first MDE 
 
-0.06 .536 .938 .905 .328 2.68 
History of suicidal ideation 
 
-1.75 0.36 0.17 .00 0.09 0.35 
History of suicide attempt 
 
-0.75 0.44 0.47 .09 0.20 1.12 
MOODS-SR-PM 
   Depressive mood 
 
0.07 0.05 1.07 .12 0.98 1.17 
MOODS-PM 
   Psychomotor retardation 
 
0.04 0.06 1.04 .52 0.93 1.16 
MOODS-PM 
   Psychotic symptoms 
 
0.02 0.14 1.02 .86 0.78 1.33 
PAS-PM 
   Separation anxiety 
 
0.11 0.09 1.12 .24 0.93 1.34 
PAS-PM 
   Agoraphobia 
 
-0.11 0.07 0.90 .10 0.78 1.02 
PAS-PM 
   Depersonalization 
 
0.02 0.08 1.02 .82 0.87 1.20 
Notes. aScore does not include suicide items; HRSD-25 = Hamilton Rating Scale for 
Depression, 25-item; QIDS-16 = Quick Inventory of Depressive Symptoms, 16-item; Q-
LES-Q = Quality of Life Enjoyment and Satisfaction Questionnaire; MDE = Major 
depressive episode; MOODS-PM = Mood Spectrum, Past Month; PAS-PM = Panic-
Agoraphobic Spectrum, Past Month 
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Table 19.  Suicidality and Illness Characteristics after Six Weeks of Treatment 
 
 
 
 
Assessment Item Group Total N Stata p 
 MDD 
N = 283 
MDD-SI 
N = 85 
 
368 
  
 N 
M 
% 
SD 
N 
M 
% 
SD 
   
HRSD Suicide 
   0 Absent 
   1 Doubtful or trivial 
   2 Mild 
   3 Moderate 
   4 Severe, attempted 
  
 
253 
17 
1 
0 
0 
 
93.4 
6.3 
0.4 
0 
0 
 
40 
27 
7 
0 
0 
 
54.1 
36.5 
9.5 
0 
0 
 
293 
44 
8 
0 
0 
72.89 .00 
QIDS Thoughts of death or 
suicide 
   0 Absent 
   1 Life is empty 
   2 Several times a week 
   3 Several times a day 
 
 
235 
23 
1 
0 
 
90.7 
8.9 
0.4 
0 
 
42 
26 
4 
1 
 
57.5 
35.6 
5.5 
1.4 
 
277 
49 
5 
1 
48.46 .00 
ISF Thought to attempt 
   Past week 
   Two weeks to 12 months ago 
   More than a year ago 
 
79 
6 
38 
35 
32.9 
7.6 
48.1 
44.3 
53 
9 
37 
7 
76.8 
17.0 
69.8 
13.3 
132 
15 
75 
42 
-  
ISF Seriously thought to 
attempt 
   Past week 
   Two weeks to 12 months ago 
   More than a year ago 
 
 
32 
0 
12 
20 
 
13.3 
0 
37.5 
62.5 
 
33 
2 
14 
17 
 
47.8 
6.1 
42.4 
51.5 
 
65 
2 
26 
37 
 
- 
 
HRSD-25 score 
 
11.63 6.73 16.16 8.74 345 
 
t = 
-4.14 
 
 
.00 
QIDS-16 
 
6.64 4.19 9.99 5.67 334 t = 
-5.55 
 
 
.00 
Q-LES-Q score 
 
42.79 9.63 40.03 9.93  t = 
2.03 
 
.04 
 
Notes.  aX2 test statistic presented unless otherwise noted; HRSD = Hamilton Rating 
Scale for Depression; QIDS = Quick Inventory of Depressive Symptoms; Q-LES-Q = 
Quality of Life Enjoyment and Satisfaction Questionnaire 
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Table 20.  Depression Severity after Six Weeks of Treatment  
 
 
 
 
 
Score Group 
 MDD MDD-SI 
 SSRI IPT SSSI IPT 
 M SD M SD M SD M SD 
HRSD-25  
 
11.70 7.17 11.57 6.30 16.46 9.07 15.86 8.51 
HRSD-25-A 
 
11.64 7.12 11.49 6.22 15.92 8.69 15.30 8.02 
QIDS-16 
 
6.57 4.32 6.72 4.07 9.14 5.06 10.81 6.17 
QIDS-16-A 
 
6.37 4.22 6.52 3.95 8.75 4.71 10.19 5.57 
Notes.  HRSD = Hamilton Rating Scale for Depression, 25-item; HRSD-25-A = Hamilton 
Rating Scale for Depression, 25-item adjusted to exclude suicide item; QIDS-16 = Quick 
Inventory of Depressive Symptoms, 16-item; QIDS-16-A = Quick Inventory of Depressive 
Symptoms, 16-item adjusted to exclude suicide item 
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5.0  DISCUSSION 
The goal of this investigation was to broaden our understanding of non-psychotic, unipolar major 
depression with current suicidal ideation (MDD-SI).  We sought to document the associated 
features of MDD-SI, understand the phenomenology of MDD-SI, develop a clinical phenotype 
of MDD-SI, and discern whether the MDD-SI phenotype is associated with an unfavorable or 
differential initial response to treatment.  We conceptualized this work as a preliminary 
investigation of the specific treatment needs of individuals with MDD-SI and potential 
identification of one subset of individuals who fail to experience an initial response to first-line 
monotherapies for major depression.  To this end, we completed a secondary analysis of data 
from a two-site, cross-national clinical trial in which individuals presenting in an episode of 
major depression were randomly allocated to an initial treatment protocol consisting of SSRI 
antidepressant pharmacotherapy (SSRI) or interpersonal psychotherapy (IPT).  
In comparisons between individuals with MDD-SI and individuals without current, 
baseline suicidal ideation (MDD), we found that (1) few pre-treatment socio-demographic or 
baseline clinical characteristics significantly distinguished MDD-SI and MDD, (2) lifetime 
experiences of suicidal ideation and suicidal behavior were significantly different between 
MDD-SI and MDD, and (3) lifetime history and past month experiences of some mood and 
panic-agoraphobic spectrum symptoms were significantly different between MDD-SI and MDD.  
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In addition, we demonstrated that MDD-SI is negatively associated with initial treatment 
response, such that individuals with MDD-SI were significantly more depressed after six weeks 
of treatment than were individuals with MDD.  Nonetheless, after six weeks of treatment, 
interviewer-rated suicidal ideation resolved for over 90% of individuals with MDD-SI and self-
reported suicidal ideation resolved for all but about 11%.  Notably, baseline group (MDD or 
MDD-SI) explained minimal between group variance in depression severity (when excluding 
suicidality) after six weeks of treatment.  Below, we discuss our main findings in detail, then the 
limitations and strengths, implications, and future directions of this work.  
5.1 TREATMENT SITE  
Preliminary analyses revealed significant differences between the Pittsburgh and Pisa samples.  
Therefore, we entered site as a covariate into all analyses for hypothesis testing. Yet, one 
supposition of using site as a covariate is that site is somehow causative.  Rather, site might be a 
measure of unmeasured cultural factors or illness characteristics.  To extend our understanding of 
these differences, we conducted unplanned, exploratory analyses.  These post-hoc analyses 
indicated that the Pittsburgh and Pisa samples differed on a number of characteristics.  Indeed, in 
all analyses, site had a significant effect on the dependent measure(s).  For example, compared to 
the Pisa sample, the Pittsburgh sample reported a longer duration of their index episode and a 
higher number of previous MDEs.  Compared to the Pittsburgh sample, the Pisa sample was 
more likely to be married and to be experiencing their first MDE.  Notably, there were no site by 
treatment interaction effects.  These findings suggest that, despite identical inclusion criteria and 
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multiple efforts to minimize site differences in the study populations recruited, the Pittsburgh and 
Pisa samples were somewhat different clinical samples.  Accordingly, some of the variance 
explained by site likely is better explained by illness features.   
 
5.2 PRE-TREATMENT SOCIO-DEMOGRAPHIC VARIABLES AND BASELINE 
CLINICAL CHARACTERISTICS 
Contrary to our expectations, only a few pre-treatment socio-demographic or baseline clinical 
characteristics significantly distinguished MDD-SI and MDD.  These included study site, 
depression severity, and current smoking status.  First, the Pittsburgh site recruited more 
individuals with MDD-SI than did the Pisa site, even after controlling for treatment site 
differences.  This is consistent with epidemiological data demonstrating strong cross-national 
differences in the prevalence of suicidal ideation between the US and Italy (Bernal et al., 2007; 
Kessler et al., 1999, 2005; Nock et al., 2008; Scocco et al., 2008).  The point prevalence rates of 
suicidal ideation, however, among study participants at the Pittsburgh site (27.6%) and Pisa site 
(18.0%) are inconsistent with previous reports.  For example, in the STAR*D study, 63% of the 
participants reported baseline suicidal ideation. 
One explanation of the low point prevalence might be our strict definition of MDD-SI.  
Whereas we categorized participants who experienced passive death ideation as MDD, other 
investigators have classified individuals with either death ideation or specific suicidal ideation as 
MDD-SI.  Had we expanded our operational definition of MDD-SI to include death ideation, 
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54.6% of our entire sample would have meet criteria for MDD-SI.  This revised point prevalence 
rate more closely approximates the prevalence of baseline suicidal ideation reported in other 
depression trials (e.g., STAR*D).  
Another explanation might be our study inclusion and exclusion criteria.  Specifically, 
while we purposely limited the number of study exclusion criteria in an attempt to capture the 
“real world” heterogeneity of individuals experiencing unipolar major depression, we excluded 
individuals who reported alcohol and drug abuse or dependence during the preceding three 
months because substance use may initiate, maintain, or exacerbate mood symptoms.  
Considering the high rates of alcohol and drug use associated with MDD-SI (SAMHSA, 2006), 
we likely excluded a percentage of individuals with MDD-SI.   
Second, as we predicted, individuals with MDD-SI were significantly more severely 
depressed at intake than were individuals with MDD.  This was consistent between interviewer-
rated (HRSD-25-A) and self-reported (QIDS-16-A) depression severity, and is consistent with 
past research (Goldney et al., 2000; Sokero, 2006).  Although statistically significant, the 
difference between the two groups’ baseline depression severity scores lacks clinical importance 
(e.g., HRSD-25-A: 23.53 versus 25.85).  The absence of a clinically meaningful difference, 
however, is noteworthy.  Using standard assessments of depressive symptomatology, and 
excluding suicidality scores, the groups' severity of depression is nearly identical.  When 
suicidality is included, however, the difference in illness severity reaches clinical importance 
(e.g., HRSD-25: 23.84 versus 27.27).  On one hand, suicidal ideation is an indicator of disease 
severity (Minnix et al., 2007; Williams et al., 2006).  If suicidal ideation denotes depression 
severity, then the presence of suicidal ideation might indicate a more severe subjective 
experience of the disease.  That is, this cognitive symptom of depression might be a proxy for 
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certain personality and psychological dimensions co-occurring with and key to the development 
of suicidal ideation, such as hopelessness, pessimism, low self-directedness, and depressogenic 
thinking.  For example, Beck and colleagues (1990) assert that if an individual is depressed and 
believes that there is no solution to his or her problems, then suicide emerges as a possible 
solution to the hopeless situation.  Although we did not measure hopelessness, some of our 
findings are compatible with this theory.  First, we demonstrated significantly lower ratings of 
life satisfaction and enjoyment in MDD-SI compared to MDD at intake to treatment.  Second, 
we found that these ratings improved after six weeks of treatment, at which time over 90% of 
interviewer-rated suicidal ideation and almost 90% of self-reported suicidal ideation had 
resolved.  Conceivably, as life satisfaction and enjoyment increase, the cognitive substrate 
changes and suicidal ideation remits, or vice versa.  
On the other hand, the absence of apparent clinically important differences in depression 
severity might be misleading.  As we argued in our research review, standard assessments of 
depressive symptomatology fail to capture a broad array of manifestations of major depression, 
including subsyndromal or temperamental features.  As we discuss later, lifetime and current 
subsyndromal and syndromal symptomatologic experiences, as measured by the more sensitive 
indicator of the disease process, the Spectrum Assessment Method, were different.  Accordingly, 
suicidal ideation might reflect both a more severe subjective and objective experience of 
depression.      
Third, with the Pittsburgh sample only (data were not available for the Pisa sample), 
smoking was associated with MDD-SI.  This is compatible with findings from other studies 
indicating a high rate of smoking among mood disorder populations (Murphy et al., 2003), and 
potentially suggestive of attempts to self-medicate, engagement in risk-taking behaviors, or 
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fewer positive coping skills (Oquendo et al., 2004).  Of note, there is some evidence that chronic 
smoking creates an antidepressant-like effect in some neurons implicated in major depression 
(Klimek et al., 2001). 
Finally, we were unable to confirm prior findings of associations between suicidal 
ideation and age, marital status, educational attainment, employment status, BMI, number of 
medical conditions, age of illness onset, number of MDEs, lifetime alcohol or substance abuse or 
dependence, or the presence of any or a particular lifetime or past month anxiety disorder.  One 
explanation is that our failure to replicate previous findings is reflective of the homogeneity of 
our sample.  For example, of the entire sample, fewer than 15% were separated or divorced and 
almost 43% were not married or living with a partner.  About 85% were an employee, 
homemaker, or student, and 22% held advanced educational degrees.  Almost 47% reported at 
least one current medical condition.   
Another explanation is that these socio-demographic variables and baseline clinical 
characteristics have limited utility for predicting current liability for suicidal ideation during 
major depression.  For instance, major depression often co-occurs with at least one other Axis I 
disorder (Feske et al., 1998; Frank et al., 2000; Sokero, 2006).  Additionally, previous studies 
indicate that a syndromal anxiety disorder comorbid with major depression increases the 
likelihood of MDD-SI (Norton, Temple, & Pettit, 2008).  Yet, of the entire sample, almost 46% 
met criteria for a past month and almost 51% met criteria for a lifetime syndromal DSM-IV-TR 
anxiety disorder.     
Of note, the absence of differences in the number of current medical conditions was 
surprising, as poor physical health is consistently associated with suicidal ideation (Alexopoulos 
et al., 2009; Russell, Turner, & Joiner, 2009).  One explanation might be our methodology for 
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coding medical conditions.  During the screening and intake process, evaluators asked potential 
participants about current and lifetime medical history.  Additionally, they completed a medical 
examination, complete with blood work.  We entered any self-reported or examiner-noted 
medical condition, regardless of severity, chronicity, or associated impairment.  While it was 
beyond the scope of this investigation to objectively classify conditions, we anecdotally observed 
substantial variance in the elaboration of the self-reports.  For example, one individual reported 
current medical conditions to be sinusitis and tendonitis.  Another individual reported Crohn’s 
disease and chronic pain.  Yet, we coded both as having two medical comorbidities.  Clearly, 
these medical comorbidities have different implications for the affected individual’s functioning 
and health status.  Nonetheless, some researchers (Dennis et al., 2007; Goodwin & Olfson, 2002) 
have demonstrated that simply reporting poor physical health, in spite of actual health status, 
increased risk of suicidal ideation – hence, our interest in looking at non-coded medical 
conditions.  For future studies, it might be informative to investigate the relationships among 
self-reported medical conditions, severity of such conditions, and MDD-SI. 
To summarize, few pre-treatment socio-demographic or baseline clinical characteristics 
significantly distinguished MDD-SI and MDD.  MDD-SI was associated with the US treatment 
site, higher depression severity, and current smoking.  The practical utility of these variables for 
predicting liability for suicidal ideation during major depression is minimal. 
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5.3 LIFETIME EXPERIENCE OF SUICIDAL IDEATION AND SUICIDE 
ATTEMPTS 
As expected, lifetime experience of suicidal ideation and suicide attempts significantly 
distinguished current MDD-SI and MDD.  In fact, lifetime experience of suicidal ideation 
consistently made statistically significant and unique contributions to logistic models predicting 
current, baseline suicidal ideation.  First, on the MOODS-Lifetime, almost 80% of individuals 
with MDD-SI but only about 23% of individuals with MDD indicated a previous experience of 
suicidal ideation for at least one three to five day period.  Thus, less than 60% of our sample had 
never experienced suicidal ideation.  Importantly, less than 20% of the MDD-SI sample were 
experiencing suicidal ideation for the first time and about 32% reported a history of making a 
plan or attempt.  These results are compatible with previous findings documenting the 
consistency of suicidal ideation across depressive episodes (Antypa, Van der Does, & Pennix, 
2010; Williams et al., 2006).  Joiner and colleagues (2003) assert that experiences with suicidal 
ideation habituate an individual to the fear, pain, and taboo associated with self-harm.  
Consequently, these previous experiences increase an individual’s risk for more severe forms of 
suicidality.  If previous or worst-point suicidal ideation are indicators of risk, then our MDD-SI 
sample is a moderate-to-high risk population.  Therefore, our findings may be generalizable to 
other at-risk samples.   
Second, almost 30% of individuals with current MDD-SI and 7% of individuals with 
current MDD reported that they had previously attempted suicide.  This overall rate of 12.2% is 
somewhat lower than that of other reports, including the 16.5% reported by Zisook and 
colleagues (2009) for STAR*D study participants.  Similar to other reports, however, in our 
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sample, as severity of suicidality increased, prevalence also decreased (Kessler et al., 1999, 
2005).   
Third, similar to previous investigations (Nock et al., 2010; Valtonen et al., 2009), we 
found that the prevalence of suicidal ideation depends on the definition of suicidal ideation and 
method for assessing it.  Specifically, there were some disagreements between self-report and 
interviewer ratings of suicidality, such that interviewer ratings were higher than were self-report 
ratings.  These findings are consistent with previous reports (Bridge et al., 2005; Joiner et al., 
1999; Nock et al., 2010; Valtonen et al., 2009).  For example, almost 33% of the MDD-SI 
sample indicated suicidal ideation on the QIDS, whereas interviewers coded almost 44% of the 
MDD-SI sample as experiencing suicidal ideation on the HRSD.  Yet, it is unlikely that this 
reflects individuals’ concealment of suicidality because of fear and stigma associated with 
suicidality: about 25% of the MDD-SI sample reported a previous suicide attempt to an 
evaluator, but only around 15% indicated a previous suicide attempt on a self-report.  Rather, the 
observed discrepancies may reflect evaluators’ assessment of certain cognitions and behaviors as 
suicidal, whereas the individual does not.  Of note, interviewer-rated suicidal ideation (HRSD) 
correlated moderately with self-reported suicidal ideation (QIDS) (r = 0.58), and interviewer-
rated suicidal behaviors (ISF) correlated strongly with self-reported suicidal behaviors 
(MOODS) (r = 0.81).  
To summarize, current MDD-SI was associated with lifetime experiences of suicidal 
ideation and suicidal behaviors.  Interviewer ratings of suicidality were higher than were self-
report ratings of suicidality, for both lifetime and current assessments.  Taken together, our 
findings underscore the importance of incorporating a lifetime assessment of suicidality into 
routine clinical practice. 
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5.4 LIFETIME AND PAST MONTH SPECTRUM CONDITIONS 
As predicted, the lifetime history and past month experience of mood and panic-agoraphobic 
spectrum symptoms were significantly different between MDD-SI and MDD.  First, MDD-SI 
was associated with significantly higher scores on the lifetime and past month MOODS and 
PAS.  Second, MDD-SI was associated with higher factor scores, including (1) MOODS-
Lifetime depressive mood, psychomotor retardation, psychotic features, and euphoria; (2) 
MOODS-PM depressive mood, psychomotor retardation, and psychotic features; (3) PAS-
Lifetime depersonalization; and (4) PAS-PM separation anxiety, agoraphobia, and 
depersonalization.  Whereas these factors contributed to the sensitivity and specificity of logistic 
regression models predicting baseline suicidal ideation, only two spectrum factors made 
statistically significant and unique contributions to any one of the four models.  These were the 
MOODS-Lifetime euphoria (Model 2) and MOODS-PM depressive mood (Model 3).  Of note, 
the other variables that uniquely and independently contributed to at least one model were site 
(Model 2 and Model 4), Q-LES-Q score (Model 2 and Model 4), and history of suicidal ideation 
(Model 2 and Model 4). Importantly, whereas only the spectrum factors which significantly 
distinguished MDD and MDD-SI in multivariate analyses were entered into the logistic 
regression models, few made statistically significant and unique contributions to the logistic 
regression models.  One explanation for this discrepancy might be the Wald statistic.  The Wald 
statistic is a measure of the significance of each independent variable’s ability to contribute to 
the logistic regression model, and is quite conservative (Tabachnick & Fidell, 1996).  Had we 
adopted a more liberal significance value, as some recommend, more spectrum factors likely 
would have made unique contributions to the models.  Fourth, contrary to our predictions, there 
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were no between group differences for MOODS-Lifetime or MOODS-PM neurovegetative 
symptoms, spirituality, or recklessness, or for PAS-Lifetime or PAS-PM panic symptoms.  
Taken together, these findings corroborate previous reports that individuals who experience 
suicidal ideation concurrent with a major depressive episode are distinct from those who do not.  
Moreover, these findings support the conceptualization of MDD-SI as phenomenologically 
distinct from MDD on a number of illness severity indices. 
First, the higher lifetime and past month MOODS and PAS total scores associated with 
MDD-SI indicate that, compared to individuals with MDD, individuals with MDD-SI experience 
a greater array of core mood and anxiety symptoms, as well as related prodromal, subsyndromal, 
attenuated, residual symptoms, and temperamental features (Cassano et al., 1997, 2009, 2010).  
Notably, these score differences remained significant even with the suicidality items excluded.  
Chiefly, this finding supports and extends the documented connection between MDD-SI and 
illness severity (Minnix et al., 2007; Williams et al., 2006).  Likewise, it provides credence to our 
speculation that suicidal ideation reflects both a more severe subjective and objective experience 
of depression.  Importantly, these findings confirm Cassano et al. (2004) and Balestrieri et al. 
(2006)’s findings that the more mood spectrum items an individual endorses, the greater the 
likelihood he or she is to endorse suicidal ideation.  Interestingly, the mean MOODS-Lifetime 
score of the MDD-SI sample, 74.29, is higher than Cassano et al.’s (2004) recurrent unipolar 
depression sample mean but lower than their bipolar sample mean, 64.8 and 83.7, respectively.   
Second, the higher lifetime and past month depressive mood factor scores associated with 
MDD-SI supports the connection between suicidal ideation and personality and psychological 
dimensions (Cassano et al., 2004, 2009; Cox, Enns, & Clara, 2004).  The depressive mood factor 
reflects core symptoms of depression, including anhedonia, and its temperamental correlates.  
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Individuals scoring high on this factor may have a reduced capacity for experiencing pleasure 
and affectively responding to the anticipation of pleasure.  They may also have high levels of 
neuroticism.  The inability to experience or anticipate pleasure might establish vulnerability to 
suicidal ideation by cultivating hopelessness and pessimism, particularly in the context of poor 
health, negative life events, or psychosocial problems.  
Third, the higher lifetime and past month psychomotor retardation factor scores 
associated with MDD-SI support and extend previous results demonstrating that depression 
severity is intimately connected to suicidal ideation (Goldney et al., 2000).  The psychomotor 
retardation factor is an indicator of severity and psychomotor changes representative of the 
melancholic subtype of major depressive episodes in DSM-IV-TR (Cassano et al., 2009).  
Specifically, melancholic depressions are characterized by severe anhedonia, loss of mood 
reactivity, psychomotor disturbances, sleep continuity disturbances and early morning 
awakenings, diminished appetite with weight loss, diurnal variation with signs and symptoms 
being worse in the morning, and guilty ruminations (APA, 2000).   
Fourth, the higher lifetime and past month psychotic features factor scores associated 
with MDD-SI is a novel, and particularly interesting, finding.  For this investigation, we defined 
MDD-SI as a non-psychotic unipolar major depressive episode with current, baseline suicidal 
ideation.  We excluded potential participants who reported a history of manic or hypomanic 
episodes, schizophrenia or schizoaffective disorder, and current psychotic symptoms.  Thus, we 
would expect minimal endorsement of psychotic symptoms, particularly past month experiences.  
The psychotic feature factor scores imply that whereas individuals with MDD-SI did not 
experience syndromal psychosis, they did experience subtle, sub-syndromal, and less severe 
aspects of psychosis.  These may include core symptoms of psychosis, as well as paranoid 
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thoughts, sensing hostility from others, feeling very vulnerable, guilty or remorseful, and being 
preoccupied with one's own problems, thoughts and feelings.   
Fifth, the higher lifetime, but not past month, euphoria factor scores associated with 
MDD-SI corroborate previous findings that the lifetime experience of manic/hypomanic 
symptoms, in the context of a “unipolar” mood disorder, increases likelihood of suicidal ideation 
(Akiskal & Benazzi, 2005; Balestrieri et al., 2006; Cassano et al., 2004, 2009).  The euphoria 
factor scores reveal positive experiences of mood elevation associated with pure mania or 
“sunny” hypomania.  This finding underscores the importance of incorporating a lifetime 
assessment of subsyndromal mood pathology – some individuals experiencing MDD-SI may not 
have a “pure” unipolar disorder.   
Sixth, the higher lifetime and past month depersonalization factor scores associated with 
MDD-SI corroborates previous findings of a connection between symptoms of depersonalization 
and suicidal ideation (Michal et al., 2010; Yoshimasu et al., 2007).  The depersonalization factor 
reflects an individual’s subjective sense of detachment from one’s own being and a sense of 
unreality.  It frequently is conceptualized as a nonspecific response to anxiety (Mula, Pini, & 
Cassano, 2007).  Researchers have documented an increased risk for depersonalization 
symptoms during adulthood among individuals with histories of childhood trauma and bipolar 
mood disorders (Mula et al., 2010).  Furthermore, researchers have evidenced the utility of 
depersonalization in mood disorders as a clinical index of disease severity, high level of 
comorbidity, and poor response to treatment (Cassano et al., 2010; Michal et al., 2010).   
Finally, the higher past month separation anxiety factor and agoraphobia factor scores 
associated with MDD-SI support previous results that anxiety is related to suicidal ideation 
(Benvenuti et al., 2010; Norton, Temple, & Pettit, 2008; Sareen et al., 2005).  Both factors reflect 
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an individual’s fear and avoidance of being alone.  Importantly, in separation anxiety the focus 
of the fear is danger to a significant other, whereas in agoraphobia the fear is panic (Aaronson et 
al., 2008).  The presence of co-occurring anxiety and panic symptoms is consistently related to 
less favorable outcomes to psychotherapy, pharmacotherapy, or their combination, to more 
severe symptom profiles, greater depression severity, and poorer quality of life (Benvenuti et al., 
2010; Frank et al., 2000; Michal et al., 2010).   
In sum, using the Spectrum Assessment Method, we documented that the lifetime and 
concurrent syndromal, subsyndromal, and trait-level symptomatologies associated with MDD-SI 
are significantly different from those related to MDD.  Chiefly, by exploring a broad array of 
manifestations of mood and anxiety disorders, we captured group differences that standard 
assessments of depressive symptomatology have not.  Mainly, our findings confirm the 
relationship between severity of depression and suicidal ideation.  They also add to the accruing 
body of evidence connecting sub-syndromal hypomanic and manic symptoms to increased 
liability for suicidal ideation.   
5.5 INITIAL TREATMENT RESPONSE 
Consistent with our hypothesis, response to an initial treatment strategy of either SSRI or IPT 
significantly distinguished MDD-SI and MDD.  Specifically, compared to individuals with 
MDD, individuals with MDD-SI were significantly more depressed after six weeks of treatment.  
Overall reductions in depression severity, as indicated by the change in HRSD-25 scores from 
baseline thru week six of treatment, were somewhat less dramatic for individuals with MDD-SI 
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compared to individuals with MDD, 40.7% versus 51.2%, respectively.  Despite this diminished 
response to treatment, after six weeks of treatment, among individuals with MDD-SI, over 90% 
of interviewer-rated suicidal ideation and almost 90% of self-reported suicidal ideation resolved.  
These findings are notable in three respects.   
First, our results indicate that baseline suicidal ideation is a nonspecific predictor and not 
a moderator of initial treatment response (Kraemer et al., 2001, 2002).  That is, the presence of 
suicidal ideation at start of treatment is related to a less favorable but not a differential initial 
treatment response to SSRI versus IPT.  Thus, the presence of suicidal ideation does not appear 
to indicate that treatment should be initiated with SSRI versus IPT.  Individuals with MDD-SI 
may represent one subset of individuals who experience a diminished initial response to first-line 
treatment for major depression, accounting for some of the previously reported variance in initial 
treatment response rates (Kessler et al., 2003a; Trivedi et al., 2006; WHO, 2005).   
Importantly, although we found that baseline suicidal ideation is a nonspecific predictor 
of initial treatment response, effect size analyses demonstrated that baseline suicidal ideation 
accounted for little of the between group variance.  One explanation might be that by entering 
baseline depression severity and treatment site as covariates, we not only partialed out the effects 
of these concomitant variables on initial treatment response, but also partialed out important 
between group differences.  For example, whereas the effect size for baseline suicidal ideation 
was 0.18, the effect sizes for site and baseline depression severity were 0.12 and 0.07, 
respectively. 
Second, our results demonstrate that suicidal ideation resolves with empirically-supported 
monotherapies for major depression.  This is compatible with previous reports documenting 
remission of MDD-SI with antidepressant pharmacotherapy, with or without an adjunctive 
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psychosocial intervention (Mulder et al., 2008; Tondo, Hennen, & Baldessarini, 2001; Tondo et 
al., 2008; Zisook et al., 2009; Alexopoulos et al., 2009).  The treatment effectiveness and 
efficiency we observed, however, is considerable, particularly compared to other studies.  For 
example, in STAR*D, 75% of individuals with MDD-SI experienced improvements in suicidal 
ideation following 12 to 14 weeks of treatment with citalopram (Zisook et al., 2009).  Similarly, 
in the PROSPECT study, older individuals with MDD-SI enrolled in the collaborative care arm 
experienced a 12.8% decline in suicidal ideation after 16 weeks of algorithm-driven treatment 
(Alexopoulos et al., 2009).  In our study, only about 10% of individuals with MDD-SI had any 
suicidal ideation after six weeks of treatment.  
One explanation for this finding might be our strict definition of MDD-SI.  Again, we did not 
classify death ideation as suicidal ideation.  After six weeks of treatment, a proportion of 
individuals with MDD-SI did report death ideation.  If we considered these individuals to be 
experiencing suicidal ideation, then our treatment response rates might be more like previous 
reports.  Yet, our separation of death ideation and suicidal ideation is consistent with the new 
CDC Classification System of Self-directed Violence (Brenner et al., 2010). 
Another explanation for the rapid resolution of suicidal ideation might be the level of care 
study participants received.  Participants in our study were engaged in a comprehensive 
treatment protocol at an academic research clinic specifically established for the conduct of 
research.  Providers were solely focused on providing care to study participants, and were free to 
provide such care without distractions or barriers, as clinically indicated.  Then again, study 
participants in the STAR*D and PROSPECT trial also received a higher-level of care than is 
usual.  In fact, a substantial proportion of participants in these two studies also received care at 
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outpatient research clinics associated with the Department of Psychiatry at the University of 
Pittsburgh. 
Third, our results support speculation that the resolution of suicidal ideation is intimately 
interwoven with the remission of major depression – alleviate the severity of the depressive 
episode, halt the suicidal process.  With six weeks of treatment, individuals with MDD-SI had 
experienced not only a dramatic reduction in suicidal ideation, but also marked decreases in 
depression severity and increases in life satisfaction and enjoyment.  This is consistent with 
previous reports evidencing declines in depression predict subsequent declines in suicidal 
ideation (Sokero, 2006).  Yet, treatment of major depression in the presence of suicidal ideation 
is less powerful than in its absence.  Does this mean treatment strategies for MDD-SI need to be 
more targeted and/or aggressive?   
From one point of view, the answer seems to be a definite, “Yes.”  This is particularly true if 
we hope to reduce suicide-related morbidity and mortality with prevention and intervention 
efforts aimed at reducing suicidal ideation (van Spijker, van Straten, & Kerkhof, 2010).  Whereas 
only a minority of individuals will transition from suicidal ideation to suicidal behaviors, a 
majority of these individuals will make this progression during the first year after initial onset of 
suicidal ideation (Kessler et al., 1999, 2005; Nock et al., 2008a).  If new treatment strategies can 
bring about a remission sooner than do current strategies, then the faster we halt the suicidal 
process, the better the outcomes.   
From another point of view, the answer seems to be a hesitant, “Yes.”  Whether (and how) 
treatments need to be more targeted and/or aggressive somewhat depends on whether the overall 
greater depression severity, phenomenological experience, or the particular psychological and 
biological substrate underlying MDD-SI accounts for the inferior initial treatment response.  For 
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example, the lifetime and past month experiences of mood and panic-agoraphobic symptoms 
were significantly different in MDD-SI and MDD.  Some of these phenomenological differences 
may be associated with a cascade of changes in biological processes and health behaviors (e.g., 
activation of the hypothalamic-pituitary adrenal axis or decreases in physical activity or sleep 
quality) (Dickerson & Kemeny, 2004; Motivala, Sarfatti, Olmos, & Irwin, 2005).  Treatments 
specifically targeting these disruptions might be helpful.  Then again, it might be that MDD-SI 
simply is a marker for a greater need for a combination pharmacological and psychosocial 
treatment strategy.  
To summarize, we demonstrated that individuals with MDD-SI might comprise one subset of 
individuals who experience a diminished initial response to first-line treatment for major 
depression.  Importantly, we found that MDD-SI is responsive to SSRI or IPT for major 
depression, just less so, and that remission of suicidal ideation is fairly rapid.  Thus, for 
individuals with MDD-SI who decline or cannot tolerate a somatic treatment, IPT is a reasonable 
treatment option.  MDD-SI might be a marker of greater severity on a number of levels and, in 
general, greater need for aggressive treatment strategies, including combination SSRI and IPT.  It 
seems unlikely that variance in treatment response is explained solely by any one factor.  Rather, 
it is likely that the inferior initial response associated with MDD-SI is like suicidal ideation itself 
– multi-dimensional.  Future studies examining the role of depression severity, 
phenomenological experience, and the particular psychological and biological substrate 
underlying MDD-SI may shed further light on the multiple pathways through which MDD-SI 
and treatment interact.      
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5.6 MDD-SI: IS IT A CLINICAL PHENOTYPE? 
Perlis and colleagues (2009) state that, to be clinically meaningful, an illness feature or subtype 
needs to improve understanding of the illness and its likely course.  Clearly, our findings are 
preliminary, and replication is needed before we can confidently argue for or against a 
conceptualization of MDD-SI as a relevant subtype and clinical phenotype of major depression.  
With that caveat, our results do indicate that conceptualizing MDD-SI as such may be valuable.  
The presence of suicidal ideation appears to be a marker for a more severe form of non-psychotic 
unipolar major depression in several respects.  Compared to individuals without baseline suicidal 
ideation, individuals experiencing MDD-SI reported poorer quality of life, greater depression 
severity, and more lifetime and past month subsyndromal and syndromal mood and panic-
agoraphobic symptoms, including previous suicidality.  Moreover, individuals with MDD-SI 
received less benefit from six weeks of either pharmacotherapy or psychotherapy, which likely 
reflects the complexity of MDD-SI.  Noting the presence of baseline suicidal ideation in the 
context of non-psychotic unipolar major depression illuminated our understanding of the illness 
and its likely course.  Accordingly, it seems reasonable to continue investigating MDD-SI as a 
potentially meaningful subtype and clinical phenotype of major depression.  
5.7 LIMITATIONS AND STRENGTHS 
The following limitations, along with aforementioned caveats, must be considered in interpreting 
our results.  First, this study was a secondary analysis of data.  We did not design the protocol, 
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including assessment methods, specifically to test our hypotheses.  Consequently, we were 
limited by our data, and certain considerations and analytical strategies were not possible.  For 
example, since study participants were randomly allocated to an initial monotherapy SSRI or IPT 
strategy, it is unclear whether initial response to a combination SSRI and IPT strategy would be 
different between MDD-SI and MDD.  Similarly, because the protocol was not designed to test 
our hypotheses, we did not have an assessment that provided details about suicidal ideation (e.g., 
onset, worst point, extent of attempt planning) or one that was originally psychometrically-
supported for use as an assessment of suicidality.  Then again, other researchers commonly 
utilize suicidality ratings from depressive symptom scales to great effect, and have demonstrated 
good-to-excellent psychometric properties for these assessments of suicidality.  Moreover, the 
instruments we did use were psychometrically validated in both English and Italian languages – 
in fact, some instruments were simultaneously developed and validated in these languages.  
Second, based on the extant literature, we adopted an all-inclusive, comprehensive, and 
structured approach to the assessment of suicidality.  Although we found smaller discrepancies 
among interviewer-rated and self-reported ratings of suicidality than have other investigators, our 
discrepancies could be a function of assessment error.  It is possible that the greater depression 
severity and overall clinical status of individuals experiencing MDD-SI affected recall or ability 
to complete accurately self-reports, including differentiating among past week, past month, and 
lifetime experiences.  Third, we applied a strict operational definition for classifying major 
depression as MDD-SI.  Whereas this somewhat hindered the comparability of our results with 
previous findings, it is consistent with the Classification System of Self-directed Violence 
(Brenner et al., 2010).  Therefore, our findings are current and should remain relevant.  Fourth, 
our operational definition of MDD-SI only included baseline suicidal ideation.  We neither 
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censored nor distinguished those few individuals with MDD who subsequently developed 
treatment-emergent suicidal ideation.  Fifth, we completed logistic regression analyses, which 
are data-driven.  Therefore, it is important to replicate the logistic regression in another sample to 
see if the results are similar.  Likewise, although we identified a set of socio-demographic, 
baseline clinical characteristics, and mood and panic-agoraphobic spectrum symptoms that 
distinguished MDD-SI and MDD, conclusions cannot be drawn concerning causation.  Whether 
inter-related characteristics of the clinical phenotype of MDD-SI precede or are consequences of 
suicidal ideation is unclear.  Finally, we observed significant differences between treatment sites.  
Based on analyses of other site differences (Frank et al., 2010), it seems very likely that some of 
the variance accounted for by “site” actually reflects differences in illness characteristics.    
Despite these limitations, our investigation is noteworthy.  To our knowledge, this is the first 
study to investigate the lifetime and current subsyndromal and syndromal symptomatology 
associated with MDD-SI.  Furthermore, this is the first study to compare a psychosocial 
monotherapy to a pharmacological monotherapy for the initial treatment of MDD-SI.  Finally, 
our data was a secondary analysis of data from a two-site, cross-national clinical trial, thus 
increasing the generalizability of our findings beyond the US. 
5.8 IMPLICATIONS AND FUTURE DIRECTIONS 
Our results highlight a few issues of clinical importance and areas for further exploration.  One, 
standard assessments of depressive symptomatology failed to capture a meaningful array of 
manifestations of major depression, including subthreshold hypomanic, depersonalization, and 
107 
 
psychotic symptoms, that distinguished MDD-SI and MDD.  These spectrum parameters may 
improve our identification and understanding of MDD-SI, including its course and treatment 
response (Benvenuti et al., 2010; Cassano et al., 2009; Frank et al., 2002, 2010).  Moreover, they 
may promote the recognition of individuals at-risk for developing MDD-SI, aiding early 
prevention and intervention efforts.  Of particular importance, individuals can generally 
complete the MOODS and/or PAS self-report in less than 40 minutes (Cassano et al., 2002).  
This is markedly less time than conventional structured clinical interviews, and provides a wealth 
of additional information. 
Two, previous experiences with suicidality, including making a plan or attempt, was the rule 
for individuals experiencing current MDD-SI.  The work of Joiner and colleagues (2003) 
suggests that these individuals are at increased likelihood for experiencing a progression of the 
suicidal process, including commencement of suicidal behaviors.  Thus, our results support the 
routine clinical practice of a lifetime assessment of suicidality to capture enduring suicide risk.   
Finally, the preliminary nature of our work means that there are a number of avenues for 
future investigations.  For example, future moderator analyses might help explain the inferior 
initial treatment response associated with MDD-SI.  Similarly, analyses of weekly symptom 
changes might illuminate which experiences drive the worsening or remission of suicidal 
ideation.  Finally, comparing treatment outcomes might illuminate whether the presence of 
current, baseline suicidal ideation inhibits remission and recovery. 
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6.0  CONCLUSION 
It is clear from the arsenal of empirically-supported pharmacological and psychosocial 
treatments for major depression that not all treatments work equally well for all individuals.  
Indeed, many individuals with major depression who access treatment will fail to experience an 
initial response.  Furthermore, a minority of these individuals will experience a worsening of 
their illness and the initiation, maintenance, or exacerbation of their suicidal ideation.  Therefore, 
understanding which individuals are more likely to respond to one treatment versus another 
would be of enormous clinical utility to mental health professionals (CDC, 2008). 
Against this backdrop, we completed an investigation of MDD-SI.  In part, we selected 
this subpopulation of major depression because suicidal ideation is multi-faceted.  It is a marker 
for future risk (Gunnell et al., 2004), a precursor to suicidal behaviors (Kessler et al., 2005), a 
cognitive symptom of depression (Cox et al., 2004), and an indicator of disease severity (Minnix 
et al., 2007).  What we did not know was whether suicidal ideation also is a predictor of who will 
experience an inferior response to empirically-supported pharmacological or psychosocial 
treatments for major depression.  We reasoned that by increasing our understanding of MDD-SI 
and initial treatment response, we ultimately could reduce depression- and suicide-related 
morbidity and mortality.  We could select the best treatment strategy from the start. 
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Similarly, we believed that one way to advance our understanding of MDD-SI was to 
move beyond the standard assessment of depressive symptomatology and syndromal 
comorbidities.  Therefore, we adopted a dimensional approach to psychopathology, the Spectrum 
Assessment Method.  With this method, we sought to capture the full range of lifetime and 
current mood and panic-agoraphobic symptoms associated with MDD-SI, as well as a range of 
behavioral traits that likely arise as a means of coping with these symptoms.  We thought that 
this method would eventually inform treatment refinement and development projects. 
We found preliminary support for our ideas.  Specifically, baseline suicidal ideation, in 
the context of a non-psychotic unipolar major depressive episode, appears to be a predictor of 
initial treatment response and to be a marker for a more severe form of depression.  MDD-SI is 
distinguished by an array of syndromal and subsyndromal mood and panic-agoraphobic 
symptoms.  To conclude, our findings provide preliminary support for the usefulness of 
conceptualizing MDD-SI as a subtype and clinical phenotype of major depression.  Further 
research, including replication of our findings, is warranted.  
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